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s UT DIARY
Premature vascular disease is an important cause of morbidity and 
mortality in Western countries and two groups particularly at risk from 
premature and extensive vascular disease are diabetic and hyperlipidaemic 
patients. In addition diabetics develop a specific microvascular disease 
affecting the capillaries resulting in retinopathy, nephropathy and 
contributing to neuropathy.
Many factors may be involved in the pathogenesis of vascular disease 
in these two patient groups. In this thesis particular attention has 
been given to the detection of enhanced platelet function as platelets 
are important in thrombosis which is often the final event leading to the 
occlusion of an atheromatous artery and platelets may contribute to the 
development of vascular disease.
The results reported in this thesis suggest that in diabetic and 
hyperlipidaemic patients there is evidence of increased zn vivo platelet 
release reaction as evidenced by the finding of elevated levels of the 
platelet-specific proteins, 3~thromboglobulin and platelet factor 4 in 
platelet-poor plasma from these patients. There is evidence also of 
enhanced activity of the platelet prostaglandin pathway in response to 
stimulation with arachidonic acid in these patients. These abnormalities 
did not appear to be related to pre-existing vascular disease in the 
patients studied. Furthermore platelets from diabetic subjects show 
diminished sensitivity to the anti-aggregatory effects of prostacyclin 
and enhanced platelet aggregation to the aggregatory agonists collagen 
and arachidonic acid when studied in whole blood. In addition the 
experimental diabetic rat produces less aortic prostacyclin than control 
rats .
These results provide evidence of enhanced platelet function in 
patients with diabetes and hyperlipidaemia which may contribute to 
their increased vascular risk. However these conclusions can only 
remain tentative until it is possible to perform long-term prospective 
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INTRODUCTION
Atherosclerosis is the commonest cause of death in Western populations. 
Mortality figures from the Registrar General's returns for England and 
Wales for 1974 indicate that ischaemic heart disease is the largest single 
cause of death in middle-aged men and a major cause of death in middle-aged 
women (Registrar General, 1977) .
By the time the clinical consequences of atherosclerosis develop, the 
disease is often in an advanced stage. In this situation, where arteries
are constricted with irregular lumens lined by calcified necrotic debris,
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therapy can often be no more than palliative. Ideally, therefore, 
attention should be concentrated on prevention.
It is probable that different stimuli can damage the arterial wall 
and produce the same final pathology of atherosclerosis. Attention has 
been focussed on factors identified from epidemiological studies as being 
associated with increased risk of development of clinical evidence of 
atherosclerosis. The term 'risk factor' is widely used to describe these 
features although not necessarily indicating a causal relationship.
A number of factors including hypertension, cigarette smoking, obesity, 
physical inactivity and stress have been implicated in the accelerated 
development of coronary artery disease (Joint Working Party of the Royal 
College of Physicians and the British Cardiac Society, 1976). It is 
not proposed to discuss these factors individually and here attention will 
be focussed on two groups particularly at risk from premature vascular 
disease, namely the diabetic and hyperlipoproteinaemic populations.
This thesis is concerned with the assessment of platelet function 
in these two high risk populations as enhanced platelet function may 
contribute to their increased vascular risk. In this introduction I will 
therefore outline the problem of diabetic vascular disease and describe 
the hyperlipoproteinaemias and their relationship to vascular disease.
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Diabetes mellitus is an important cause of secondary lipid and lipoprotein 
abnormalities and I will describe the altered lipoprotein metabolism in 
diabetes as the results of the platelet studies to be reported will be 
correlated not only to glycaemic control but also to individual lipid and 
lipoprotein concentrations in the diabetic subjects, I will describe 
platelet physiology and highlight the recent understanding of the importance 
of the prostaglandin pathway in platelets. The importance of platelet/ 
vessel wall interactions has been emphasized in recent years and I will 
detail the physiology of prostacyclin which probably is important in this 
regard. Platelets will be discussed in relation to thrombosis and 
atherogenesis and the rationale for studies of platelet function in diabetic 
and hyperlipoproteinaemic subjects will be discussed.
Diabetes and Vascular Disease
Large vessel disease has become the commonest cause of death in the 
diabetic population. Although the average life span of diabetics has 
greatly increased since the advent of insulin, they still have a shorter 
life expectancy than non-diabetics. The already high incidence of 
vascular disease in non-diabetic Western populations appears to be still 
higher in diabetics; cardiovascular disease was responsible for 79% of 
deaths in diabetic patients at the Joslin Clinic in 1966, contrasting 
with a 54% death rate due to cardiovascular disease in the general 
population during the same year (Marks and Krall, 1971).
Although there have been suggestions of a specific diabetic large 
vessel disease (Lundbaek, 1973) there is little evidence to suggest that 
atherosclerotic lesions in diabetics are distinct from those in non­
diabetics (Strandness e t  ai^ 1964). However, atherosclerosis appears 
to be more extensive and to develop at an earlier age in diabetic patients 
(Robertson and Strong, 1968). These pathological findings are in agreement 
with clinical studies, the most convincing evidence coming from the
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prospective community study in Framingham. All major clinical 
manifestations of atherosclerosis were found to have an increased 
incidence in diabetics (Garcia, gt aZ^1974).
Many factors may contribute to the increased incidence of large 
vessel disease in diabetic patients as in non-diabetic subjects, however, 
this increased incidence in diabetes is not fully explainable in terms of 
known risk factors (Jarrett et  aly 1982). Therefore other metabolic 
abnormalities have been sought in diabetic subjects which might contribute 
to the increased vascular risk. In this thesis platelet function will 
be studied in diabetic patients because of the postulated role of platelets 
in the early lesions of atheroma and their undoubted importance in the 
development of thrombus on pre-existing atheromatous plaques which leads to 
final arterial occlusion.
In addition to the high incidence of atherosclerosis, diabetics also 
develop a specific vascular disease involving small vessels. This micro­
angiopathy, which is characterised by a thickened but paradoxically 
leaky capillary basement membrane, makes an important contribution to 
morbidity and mortality in the diabetic population principally through 
retinopathy, nephropathy and neuropathy (Keen and Jarrett, 1982).
It is generally agreed that the development of microvascular disease 
in diabetics is a result of the metabolic derangement plus time. However 
the actual pathogenesis of the capillary lesion is poorly understood. It 
has been postulated that abnormal platelet function may play a role in 
the development of microvascular disease (Colwell e t  a t , 1978). Therefore 
in this thesis the diabetic patients studied will be carefully clinically 
examined to determine the presence or absence of the different diabetic 
vascular complications and the results of the parameters of platelet 
function will be analysed on this basis.
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Lipoproteins
The major plasma lipids, triglyceride, cholesterol esters, free 
cholesterol and phospholipids are held in solution in the form of complex 
water-soluble molecular aggregates known as lipoproteins. Various 
analytical techniques, including electrophoresis, preparative ultra­
centrifugation and measurement of lipid and protein contents of the various 
lipoprotein classes, have led to a dramatic increase in the understanding 
of the composition of these conplex particles and have provided the basis 
for their classification (Table 1 ) I
Chylomicrons are the largest of the lipoprotein species, and are 
normally found in plasma only after a meal. They serve to transport 
dietary fats from the small intestine via the lymphatic system to the 
thoracic duct where they enter the blood stream. They are rich in 
triglyceride and contain only 1-2% protein by weight. The apoprotein 
component of newly formed chylomicrons is apoprotein B-48 and in lymphatics 
and circulation chylomicrons acquire other apoproteins of the C and E 
groups (Havel e t  aZ, 1973). The triglyceride content of chylomicrons is 
hydrolysed to free fatty acids by the enzyme lipoprotein lipase which has 
its site of action on capillary endothelium of skeletal muscle and adipose- 
tissue (Blanchette-Mackie and Scow, 1971) . The free fatty acids are either 
oxidised for fuel or re-esterified in adipose tissue for storage as 
triglyceride. The chylomicron remnant after removal of the triglyceride 
core dissociates from the capillary endothelium and is taken up by liver 
via a receptor-mediated process involving apoprotein E.
Very low density lipoprotein (VLDL) serve to transport endogenously 
synthesized triglyceride. They are synthesized in the liver and to a 
lesser extent the intestine (Roheim e t  aZ, 1966; Windmueller e t  aZ^ 1973; 
Noel and Rubinstein, 1974). VLDL secreted by the perfused liver contain 
both apoprotein B and apoprotein C ^whereas apoprotein C is absent from VLDL
13






Chylomicrons 2.5 85 4 8
VLDL 10 50-55 15 18
LDL 20-25 12 30 22
HDL 50 6 15 25









Chylomicrons 80.0 109 0.93 origin
VLDL 25.0-80.0 107 0.97 pre-beta
LDL 17. 5-25.0 2.3 X loG 1.03 beta
HDL2 8. 5-15.0 3. 6 x 105 1.09 alpha2
HDL 3 7. 0-9.0 1. 7 x 105 1. 15 alphag
Table le, AooliDooroteLns of Human Serum
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APOLIPOPROTEIN DENSITY CLASS MOLECULAR WEIGHT (daltons x 10“ )̂
CONCENTRATION
( m g / Z )
A-1 HDL 28 800-1200
A-11 HDL 17 300-500
A-111 HDL 21 20-40
B LDL,VLDL 275 700-900
C-1 VLDL,HDL 7 30-70
C-11 VLDL,HDL 8_5 30-50
C-111 VLDL,HDL 8 .5 80-120
E VLDLVHDL 39 30-60
D-2 HDL 7 10-20
(Assmann and Schjpitz, 1979)
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in intestinal lymph (Windmueller et aZ-j 1973). It is not known whether 
hepatic VLDL are secreted with a full component of apoprotein C, but 
available evidence suggests that apoprotein C is transferred from high 
density lipoprotein (HDL) in the circulation (Herbert e t 1978). VLDL, 
like chylomicrons, undergo hydrolysis of their triglyceride content by the 
enzyme lipoprotein lipase acting in peripheral tissues. During the catabolism 
of VLDL the majority of apoprotein B is conserved while surface components 
including phospholipid and apoprotein C transfer to HDL. Turnover studies 
using radioactively-labelled lipoproteins have demonstrated that VLDL are 
mainly converted to low density lipoprotein (LDL) in the circulation via 
intermediate density lipoproteins (IDL)(Eisenberg and Levy, 1975). IDL 
can also be taken up directly by the liver.
LDL are cholesterol-rich particles responsible for transport of 
approximately 70% of the total plasma cholesterol. These particles are 
not normally synthesized by the liver but are virtually all derived from 
the metabolism of VLDL (Eisenberg and Levy, 1975) . LDL serve to deliver 
cholesterol to peripheral cells and the pathway of catabolism of LDL has 
been delineated by Brown and Goldstein (1976). Briefly, there are specific 
high affinity receptors on cells which recognise LDL apoprotein B. The 
receptor bound LDL is internalised by a process of absorptive endocytosis.
The resultant endocytotic vesicle fuses with lysosomes where the cholesterol 
esters of LDL are hydrolysed to yield free cholesterol. The free cholesterol 
diffuses from the lysosomes into the cell cytoplasm where it may be used 
for membrane synthesis. In addition this cholesterol has regulatory actions 
on cholesterol metabolism within the cell; it suppresses synthesis of LDL 
receptors, suppresses cholesterol synthesis and stimulates its own re- 
esterification. This receptor mediated pathway accounts for about two- 
thirds of the LDL which is degraded daily - 1000 mg LDL-cholesterol. In 
addition a further 500 mg of LDL-cholesterol is cleared from plasma by a 
receptor-independent scavenger mechanism.
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HDL particles account for about 20-30% of the total plasma cholesterol. 
There is considerable heterogeneity within HDL and the particles contained 
within the HDL fraction arise from several different sources including 
direct synthesis by the liver and intestine and as a bi-product of the 
metabolism of triglyceride-rich lipoproteins. Whilst the liver is able 
to synthesize both apoprotein A and apoprotein C, HDL of intestinal origin 
appears to contain apoprotein A only (Windmueller e t  aZ^ 1973). HDL may 
facilitate net cholesterol removal from all membranes in  v ivo and serve 
to transfer cholesterol from peripheral cells to the liver for excretion.
HDL cholesterol is the preferred substrate for lecithin-cholesterol acyl- 
transwer as e (LCAT)(Akanuma and Glomset, 1968) which catalyzes the estérification 
of cholesterol by transfer of fatty acid from the C-2 position of phosphatidyl­
choline. The reaction takes place mainly on or within the lower molecular 
weight sub-fractions of HDL (Glomset e t  aZ^ 1966). An important activator 
of this enzyme is apoprotein A-1, the main protein component of HDL 
(Fielding e t  aZ^ 1972) . The HDL/LCAT enzyme complex can therefore act 
as an acceptor of cellular cholesterol.
Lipoproteins and Vascular Disease
One of the most striking features of the atherosclerotic lesion is the 
accumulation of cholesterol ester which deposits in the proliferating 
smooth muscle cells and in the surrounding interstitial space of the arterial 
intima and media. Although the histology of the atheromatous plaque is 
complex, a number of lines of evidence suggest that cholesterol may play 
a central role in its development. Severe atherosclerosis can be produced 
in many species of experimental animal by feeding a diet that raises the 
plasma cholesterol level (Roberts and Straus, 1965). Proliferative 
thickening of the arterial wall can be produced in animals by trauma, such 
as hypertension or by destruction of the endothelium by physical or chemical 
methods. However the lesion formed remains a simple scar unless the
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animal is made hypercholesterolaemic, when severe atherosclerosis 
develops (Wissler, 1973).
Studies in human populations have shown that symtomatic atherosclerosis 
does not frequently develop even when there are predisposing factors, such 
as cigarette smoking, hypertension or diabetes mellitus, unless the mean 
concentration of serum cholesterol in the population exceeds 4 mmol/I 
(Epstein, 1971; Stamler, 1973 and Keys, 1975). A single gene-determined 
disorder familial hypercholesterolaemia, in which there are markedly 
elevated plasma and tissue cholesterol levels is accompanied by accelerated 
atherosclerosis at an early age without other contributing factors, such 
as hypertension, smoking or diabetes mellitus being present (Frederickson 
et  aly 1978)
This apparent central role of cholesterol in the pathogenesis of the 
atheromatous plaque provoked many epidemiological and clinical studies 
which examined the relationship between plasma cholesterol and atherosclerosis, 
It is now long established that there is in fact a strong positive correlation 
between plasma cholesterol and atherosclerosis but stronger relationships 
are seen for the major cholesterol carrying lipoproteins — •
LDL and HDL. Increasing
concentrations of plasma LDL cholesterol are strongly and independently 
predictive of coronary artery disease and account for the association seen 
with total cholesterol (Gordon e t  dty 1981). Equally HDL cholesterol 
concentrations are strongly and independently predictive of coronary disease 
and in some studies more so than LDL (Miller e t  a l  y 1977; Goldbourt and 
Medalie, 1979). However the association with HDL is inverse, in other 
words decreasing HDL cholesterol concentrations are associated with 
increasing risk of coronary artery disease.
Although these epidemiological findings have not yet been fully 
explained in biological terms more and more evidence is accumulating
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implicating LDL and HDL in the biochemistry of atherosclerosis.
Cholesterol deposited in the atheromatous lesion is derived from 
plasma (Zilversmit, 1968) and LDL enters the arterial wall at a rate 
directly related to its plasma concentration (Nicoll e t  dty 1981). The 
foam cells so characteristic of atheroma may have their origin in macrophage 
monocytes which have receptors for chemically altered LDL. Unlike normal 
LDL receptors they are not down regulated by increasing cellular cholesterol 
concentrations (Goldstein e t  aZy 1979). One type of chemically altered 
LDL taken up by macrophages resulting in massive cholesterol accumulation 
in these cells is malondialdehyde-modified LDL (Forgelman e t  aZy 1980).
Another mechanism by which LDL cholesterol might accumulate in cells is by 
fluid phase endocytosis which is independent of receptors (Steinberg, 1981).
LDL has other potentially important effects in relation to the pathogenesis 
of atherosclerosis. It can be directly toxic to arterial endothelial cells 
(Ross and Harker, 1976) and endothelial injury results in increased passage 
of LDL from plasma into the arterial intima. In addition LDL can be 
directly mitogenic to smooth muscle cells (Fless e t  aZy 1982). As well as 
tire se potentially important pathogenic effects LDL has important interactions 
with blood platelets as will be discussed later.
It has been postulated that HDL might exert its apparent protective role 
against the development of atherosclerosis by returning cholesterol from 
peripheral cells to the liver for excretion (Miller and Miller, 1975).
HDL with the enzyme LCAT (HDL
cholesterol is the preferred substrate for LCAT and apoprotein AI, the 
main apoprotein of HDL is an important activator of the enzyme) might 
facilitate net cholesterol removal from cell membranes by acting as an 
acceptor for cellular cholesterol (Glomset, 1968). I n  v i t r o  studies where 
HDL has been shown to enhance cholesterol efflux from cultured cells support 
this hypothesis (Stein and Stein, 1973; Stein e t  aZy 1975). It is the HDL
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subfraction HDL^ which is the initial acceptor of cholesterol (Rothblat 
and Phillips, 1982) and one proposed pathway among others for return of 
cholesterol to the liver involves the conversion of HDL^ to HDLg which in 
turn acquires apoprotein E to form HDL^. HDL^ can be rapidly taken up 
by hepatic cells by specific receptor mediated processes which recognise 
apoprotein E (Mahley, 1982). Alternatively HDL may be produced in the 
periphery at a rate depending on cholesterol efflux from cells. This 
suggestion is based on the finding that cholesterol efflux from some cells 
is accompanied by secretion of apoprotein E (Basu e t  a t y 1981). In addition 
to its possible role in reverse cholesterol transport HDL has other effects 
which may be important in the development of atherosclerosis. HDL^ which 
contains apoprotein E can compete with LDL for binding to the LDL receptor 
therefore reducing LDL uptake (Miller e t  aty 1977).
The relationship of increasing plasma triglyceride levels to vascular 
risk is not so well defined as for plasma cholesterol and the cholesterol- 
rich lipoproteins. In some prospective studies, an independent relationship 
between plasma triglyceride levels and the development of vascular disease 
has been reported (Carlson and Bottiger, 1972), but this relationship has 
not been a universal finding (Wilhelmsen e t  aty 1973; Rosenman e t  aty 1976).
In a more recent prospective study (Pelkonen e t  aty 1977) of a large group 
of middle-aged Finnish men followed over a 7-year period, an independent 
association was found between cardiovascular mortality and fasting serum 
triglyceride levels. This study is open to criticism for a number of 
reasons. There was à substantial loss of the original cohort to follow-up, 
and in addition hypertension, an important predictor of vascular risk, was 
not included in the analysis. However, perhaps the most important criticism 
is that HDL levels were not measured. There is an inverse correlation 
between VLDL, the major triglyceride-rich
lipoprotein and HDL and it is possible that the association between VLDL
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and vascular risk is not independent and may be explained by the inverse 
relationship between VLDL and HDL (Hulley e t  aty 1980).
Chylomicrons do not appear to be related to atherosclerosis as in 
Type 1 hyperlipoproteinaemia where there is massive accumulation of these 
particles there does not appear to be an increased incidence of vascular 
disease. On the other hand recent evidence from in  v i t r o  studies does 
suggest that VLDL may play a role in the development of atherosclerosis 
through their ability to deposit lipid in cells of the arterial wall. 
Although normally VLDL are not recognised by the classical LDL receptor 
it appears that VLDL from hypertriglyceridaemic subjects can bind to and 
be taken up by the LDL receptor mechanism in cultured fibroblasts and 
this process is related to the apoprotein E content of the particles 
(Gianturco e t  aty 1983). In addition VLDL can be taken up by receptors 
on cultured macrophages which appear to be distinct from the LDL receptor 
and the receptor for modified LDL. This receptor has been designated the 
3-VLDL receptor (Kraemer e t  aty 1983). By this pathway therefore VLDL 
could produce massive lipid accumulation in macrophages.
Hyperlipoproteinaemias
Classification of the hyperlipoproteinaemias in the absence of an 
understanding of primary aetiological and pathophysiological mechanisms 
are mainly operational and have become possible with the development of 
techniques for the qualitative and quantitative separation of the individual 
lipoprotein species. The most widely accepted classification is based on 
measurement of fasting total serum cholesterol and triglyceride levels 
together with lipoprotein electrophoresis (Frederickson e t  a t y 1967;
Beaumont e t  a t y 1970). In addition, ultracentrifugation of serum is 
important for the demonstration of the abnormal apoprotein B-containing 
lipoprotein of type III hyperlipoproteinaemia which floats in the 
d < 1.006 g/ml fraction. The new precipitation techniques allow for simple
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measurement of LDL (Burstein e t  a t y 1970) and VLDL (Ononogbu and Lewis,
1976) in patients with mixed elevations of cholesterol and triglyceride.
On the basis of these measurements, six lipoprotein phenotypes have 
been described (Table 2 ). This classification has limitations because 
it is based entirely on laboratory operational techniques. Firstly it 
is clear that a particular lipoprotein abnormality may result from more 
than one pathological mechanism; for example, the type IV abnormality 
may be an expression of decreased clearance of VLDL or due to over synthesis 
of VLDL or both. A second major limitation of the typing system is in the 
area of genetics. No specific type of hyperlipoproteinaemia can be 
considered to be genotypic and this limitation has been particularly 
emphasized by the description of familial combined hyperlipoproteinaemia 
which appears to be due to a single autosomal dominant gene although the 
plasma lipoprotein pattern may be variable in affected individuals 
(Goldstein e t  a t y 1973).
Fasting serum concentrations of cholesterol and triglyceride, together 
with lipoprotein typing using cellulose acetate electrophoresis have been 
measured in a large carefully documented, randomly selected group of men 
and women employed in a light industrial factory in North-East London 
(Lewis e t  a t y 1974). Despite the fact that the upper cut-off points for 
serum cholesterol and triglyceride concentrations were intentionally set 
high (7.75 mmol/1 for cholesterol and 2.0 mmol/1 for triglyceride), the 
prevalence of hyperlipoproteinaemia in this healthy population of 276 
subjects was high; 17% of men and 8% of women having hyperlipoproteinaemia. 
4.3% of men and 4.8% of women, aged 40-69 years, had hypercholesterolaemia 
and 14% of men and 3% of women in this age range had hypertriglyceridaemia 
(Lewis e t  a t y 1974). In another study (Lorimer e t  a t y 1974) a similar 
high frequency of hyperlipoproteinaemia was found in a series of 4,385 
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proteinaemia was 15.3%, 12% with type IV hyperlipoproteinaemia and 3%
with type II hyperlipoproteinaemia.
Lipoproteins and Diabetes Mellitus
A large number of studies have demonstrated a high frequency of lipid 
and lipoprotein abnormalities in diabetic subjects. In a large group of 
newly diagnosed diabetics (both insulin dependent and insulin independent) 
over 40% had fasting plasma triglyceride concentrations greater than 2 mmol/1 
(Hayes, 1972). Similar results were reported in a large group of insulin 
dependent children prior to treatment (Chance e t  a i , 1969). A high 
frequency of hypertriglyceridaemia is also found in diabetics established 
on treatment. In one study of 102 non-insulin dependent diabetics over 
30% had fasting triglyceride concentrations above 2 mmol/1 (Hayes, 1972) 
and of 98 randomly-selected diabetics of whom about a third were insulin- 
taking 22% had fasting triglyceride concentrations greater than 1.7 mmol/1 
(Wilson e t  a i , 1970). The hypertriglyceridaemic group in this study were 
distinguished by greater hyperglycaemia and relative body weight. In a 
large mixed group of diabetic patients aged 5-85 years, diabetics over the 
age of 30 years had significantly higher triglycerides than non-diabetics 
but no differences were found in the under 30 age group (New e t  aiy 1962). 
However fasting triglyceride levels in 270 juvenile diabetics on admission 
to Summer camps were higher than controls of comparable age (Kaufmann e t  
aty 19753. Similarly an older group of diabetics studied as part of the 
Framingham community prospective study showed significantly elevated mean 
triglyceride levels in both male and female diabetics compared to non­
diabetic subjects in the same community (Garcia e t  aty 1974).
It has been stated that "hypertriglyceridaemia is the hyperlipidaemia 
par excellence of the diabetic" (Albrink, 1974) . However some studies 
have shown a high frequency of hypercholesterolaemia in diabetics. Cholesterol 
levels were significantly higher in 195 established diabetics aged 5-85 years
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compared to controls throughout all age ranges (New e t  dt^ 1962). Similarly 
in a large group of young insulin dependent subjects mean cholesterol levels 
were higher than controls in both boys and girls (Kaufman e t 1975). In 
the Framingham community prospective study mean cholesterol concentration 
was significantly higher in diabetic women but not in diabetic men (Garcia 
e t  al^ 1974). Other studies have shown that the frequency of hypercholesterol- 
aemia is similar to that of hypertriglyceridaemia in diabetics (Hayes, 1972; 
Wilson e t  dl^ 1970; Kaufmann e t  at^ 1975; Schonfeld e t  d l , 1974). More 
recently LDL-cholesterol concentrations have been measured in diabetic 
subjects. No difference in mean LDL-cholesterol concentrations was found
r
in longstanding insulin dependent subjects conq)ared to control subjects in 
a study from Helsinki (Nikkila and Hormila, 1978) but LDL cholesterol levels 
were higher in young insulin dependent subjects (Sosenko e t  dl^ 1980).
Elevated LDL-cholesterol was found in insulin dependent men but not insulin 
dependent women in a study from London (Mattock e t  d l , 1979) but no differences
were seen for either sex in Tecumseh (Ostrander e t  dly 1980) or Framingham
(Kannel e t  a t , 1979). However among Pima Indians with non-insulin dependent 
diabetes LDL-cholesterol was significantly elevated (Howard e t  a t , 1978). 
Although these findings with regard to LDL-cholesterol concentrations in 
diabetics are not consistent it is important to remember that LDL-cholesterol 
is a very powerful risk factor in all individuals including diabetics.
Since the re-awakening of interest in HDL and its apparent protective 
role in atherosclerosis several studies have been performed in diabetic 
populations. These studies have shown conflicting results but they are 
probably explained by differences in the diabetic groups studied. It is 
now becoming clear that HDL concentrations tend to be low in non-insulin
dependent subjects (Howard e t  a t , 1978; Lopes-Virella e t  a t , 1977; Kennedy
e t  a t , 1978; Nikkila, 1978; Taylor e t  a t , 1981). However in insulin 
dependent diabetics HDL-cholesterol concentrations tend to be equal to or
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higher than in non-diabetic controls (Elkeles e t  a l , 1978; Eckel e t  a l ,
1981; Wille and Aarseth, 1974). In a study from Helsinki the only 
difference between lipoprotein concentrations in longstanding insulin 
dependent diabetics and controls was that the former had significantly 
higher HDL cholesterol concentrations (Nikkila and Hormila, 1978). This 
elevation in HDL in insulin dependent diabetics appears to be due to an 
increase in the HDL2 sub-fraction (Eckel e t  a l , 1981) low levels of which 
are most closely related to the risk of atherosclerosis. So HDL levels 
certainly do not explain the predisposition of insulin dependent diabetics 
to large vessel disease.
The pathophysiology of the altered lipid and lipoprotein levels in 
diabetes mellitus has received considerable attention. LDL binding to 
its cell surface receptor and its subsequent internalisation and degradation 
is stimulated by physiological concentrations of insulin in tissue culture 
cells (Chait e t  a l , 1978) probably by increasing receptor numbers 
rather than receptor affinity (Chait e t  a l , 1979). Recent studies using 
the euglycaemic clamp technique support these findings in that LDL 
degradation by peripheral blood mononuclear cells was stimulated following 
a 4 h insulin infusion of 1 mU/kg/min in healthy young men (Mazzone e t  a l ,
1984). In this study there was also accelerated clearance of LDL from
plasma. In addition to possible effects of the diabetic state on LDL 
receptor activity it appears that LDL apoprotein B is susceptible to 
glycosylation and glycosylated LDL shows reduced binding to the LDL 
receptor (Gonen e t  a l , 1981; Witztum e t  a l , 1982). Modification of 5% or 
less of the lysine residues of LDL apoprotein B led to decreased LDL catabolism 
(Steinbrecher e t  a l , 1984).
Different pathophysiological mechanisms may be responsible for raised 
VLDL-triglyceride concentrations depending on the type of diabetes. Insulin
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dependent diabetics may have defective clearance of VLDL from the circulation 
(Nikkila and Kekki, 1973; Bagdade e t  a l , 1967). Lipoprotein lipase, the 
enzyme responsible for the hydrolysis of VLDL triglyceride, depends for 
its full activity on adequate insulin concentrations and in insulin 
deficiency lipase levels are reduced (Nikkila e t  a l , 1977; Jones e t  a l ,
1966). In addition increased production of VLDL has been reported (Nikkila 
and Kekki, 1973) and in some instances especially with severe hypertriglycerid­
aemia an underlying primary hypertriglyceridaemia may be present (Brunzell 
e t  a l , 1975; Chait e t  a l , 1981). In non-insulin dependent diabetic subjects 
the pathophysiology of hypertriglyceridaemia is more complex and both 
decreased catabolism of VLDL (Lewis e t  a l , 1972) and over production 
(Kissebah e t  a l , 1982; Abrams e t  a l , 1982) have been described. It is 
probable that VLDL production is increased when free fatty acid levels are 
increased (Nikkila and Kekki, 1973; Abrams e t  a l ,  1982) and normal when 
free fatty acids are not increased (Howard e t  a l ,  1983).
Differences in HDL concentrations among different types of diabetic 
patients may be in part a reflection of the activity of the enzyme lipoprotein 
lipase (Nikkila, 1978; Nikkila e t  a l , 1978) as many of the components of 
circulating HDL are not secretory products but are derived from transfer 
of apoproteins, phospholipids and triglycerides from triglyceride-rich 
lipoproteins and the estérification of free cholesterol by the 
LCAT enzyme.(Nichols and Smith, 1965; Chajek
and Eisenberg, 1978). Therefore one possible determinant of plasma 
HDL levels is the rate of catabolism of triglyceride-rich lipoproteins 
and indeed correlations have been described between HDL and lipoprotein 
lipase activities in both normal (Nikkila et  a l , 1978) and diabetic 
subjects (Nikkila and Hormila, 1978; Nikkila, 1978). Recently it has been 
demonstrated that HDL can be glycosylated (Schleicher e t  a l , 1981; Witztum 
e t  a l , 1982). However the significance of this finding remains to be 
determined.
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Lipid and lipoprotein abnormalities do not explain the increased 
prevalence of vascular complications in the diabetic population. In 
fact all known risk factors taken together do not fully explain this 
increased risk. However lipid and lipoprotein abnormalities are 
certainly closely associated with vascular disease in diabetics as they 
are in non-diabetics. Mean fasting triglyceride concentrations were 
significantly higher in diabetics with complications than in those without 
(New et  d l , 1962). No difference was seen in mean cholesterol concentration 
However in this study complications included nephropathy, retinopathy and 
neuropathy as well as large vessel disease. Fasting triglyceride and 
cholesterol concentrations have been analysed in relation to diabetics 
with and without large vessel disease (Santen et  a t , 1972). The groups 
were reasonably well matched for age, type of treatment and duration of 
diabetes but smoking habits were not assessed. Diabetics with large 
vessel disease had significantly higher plasma triglycerides than controls 
in the age range 30-59 years and a similar trend was seen for the age 
group 60-69 years. Cholesterol levels were higher in the younger age 
group with complications but the relationship was not as strong as that 
for triglyceride (Santen e t  d l , 1972). However other studies have 
emphasised the relationship between cholesterol levels and vascular disease 
in diabetics (Lamba . e t  d l , 1974) but some studies have found no association 
with either cholesterol or triglyceride levels and vascular complications 
in diabetics (Elkeles e t  a l , 1971). More recently relationships have 
been sought between individual lipoprotein concentrations and vascular 
disease in diabetics because in the general population lipoprotein levels 
are better predictors of vascular risk than total lipid levels. In a 
cross-sectional study of 154 diabetics (48 non-insulin dependent and 106 
insulin dependent subjects) clinical evidence of large vessel disease was 
more likely to be present when lipid and lipoprotein concentrations were
29.
high (Reckless e t  a l , 1978) and the previously reported strong associations 
between triglyceride concentrations and the presence of vascular disease 
were supported the same relationships being found for VLDL, However 
these associations disappeared after an analysis of variance. This has 
also been emphasised in not-diabetic populations and may be explained by 
the inverse association between VLDL and HDL (Hulley e t  a l , 1980). However 
significant associations with vascular disease remained after the analysis 
of variance for LDL-cholesterol and HDL-cholesterol concentrations but 
these associations were not present in all diabetic sub-groups. LDL- 
cholesterol concentrations remained positively associated with vascular 
disease in male diabetic patients on insulin whereas HDL concentrations 
remained negatively associated with vascular disease in all female diabetics 
(Reckless e t  a l , 1978). The relationship of HDL to vascular disease in 
female diabetics has also been demonstrated in a prospective study where 
the especially high incidence of coronary artery disease in diabetic 
women with HDL-cholesterol levels below 0.88 mmol/1 was emphasised. In 
these circumstances the apparent protection of women from the development 




Platelets which, like red blood cells, do not contain a nucleus, 
are the smallest of the formed elements of blood circulating 
as biconcave discs approximately 2-3 pm in They are formed
from megakaryocytes which in the final process of maturation become 
amoeboid in shape and pseudopods penetrate the marrow sinusoids. These 
pseudopods fragment in the blood flow with the nucleus remaining in the 
bone marrow (Penington, 1981). The normal circulating platelet count 
varies in man between 150 and 400 x 10*/1 (Dacie and Lewis, 1975) and 
mean platelet survival is about 9.9 days (Harker and Finch, 1969).
Platelets are removed from the circulation in the spleen and liver (Aster,
1969).
Platelets have a central role in normal haemostasis. Through their 
properties of adherence to vascular or foreign surfaces and their 
aggregation with other platelets they can initiate haemostasis. Platelets 
also participate in the fluid phase of coagulation through their active 
biochemical contents and by providing surfaces for reactions to take 
place. Platelets may also contribute to the development of atherosclerosis
Historical Aspects
Robb-Smith (1967) has provided a fascinating account of the early 
descriptions of blood platelets which depended on the development of 
microscopic techniques of sufficient resolution. From Robb-Smith*s 
researches it is probable that it was George Gulliver in 1841 who made 
the earliest representations of blood platelets which were included in an 
appendix and notes to an English translation of Gerber's "General and 
Minute Anatomy". However Gulliver made it clear that he did not think
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that platelets were associated with fibrin formation. On the other hand 
William Addison an almost exact contemporary of Gulliver described the 
'minute molecules' or 'granules' in relation to the formation of 'delicate 
and perfectly cylindrical filaments or fibres ....'. Addison's article 
'On the Colourless Corpuscles and on the Molecules and Cytoblasts in the 
Blood' was accompanied by illustrations which leave no doubt that he was 
observing a platelet-fibrin clot. Franz Simon, a Berlin biochemist 
performed microscopic studies in blood treated with ferrocyanide to prevent 
clotting and saw numerous 'small bodies' (almost certainly platelets).
This observation was repeated by Gustav Zimmermann, a German military 
physician who observed 'billions' of small colourless bodies which 
he called elementary bodies. Robb-Smith (1967) points 
out the scathing attack made on these findings by Rudolf Virchow in 'Die 
Cellularpathologie' which appeared in 1858, Virchow himself suggesting 
that the elementary bodies were artifacts. Virchow of course made a major 
contribution to pathology with the concept of thrombosis and embolism but 
an English physician, William Kirkes first recognized the nature of 
arterial embolism and infarction in 1852 and an English opthalmic surgeon 
Thomas Wharton Jones described the stages of thrombosis. Jones in an 
essay 'On the State of the Blood and Blood Vessels in Inflammation' 
observed 'arteries becoming blocked up by a mass composed apparently of 
colourless corpuscles and fibrin .... By and by the plug was pushed along 
in the artery by the force from behind and the flow of blood was re­
established down to the first considerable branch above this place where 
the plug again stopped. A portion of the plug of granulous substance 
becoming detached and carried away, the mass was reduced in size so that 
it admitted of being again forced on .... I have found that on pressing 
the web over an artery or vein - a large vein especially - pretty firmly 
with a blunt point, an agglomeration of colourless corpuscles with a few
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red ones, held together apparently by coagulated fibrin, occurs, adheres 
to the wall of the vessel and more or less completely obstructs it at the 
place .... In some cases I have been able to satisfy myself that the 
plugs of grey granulous substance consisted of colourless corpuscles, 
agglomerated and held together by a tenacious looking matter, probably 
coagulated fibrin. In other cases it appeared to me that the grey 
substance consisted of minute granules, held together by the tenacious 
matter*. This account of observations in a traumatised vessel in the 
web of a frog's foot is clearly the formation of fibrin platelet thrombi. 
Other important contributions in the development of the understanding of 
the nature of platelets and their relationship to thrombosis followed. 
Professor Max Schultze of Bonn in 1865 developed a method for keeping 
blood warm during microscopic analysis and observed the coalescence of 
platelets into granular masses (Koernchenhaufen), and in addition he 
appreciated the relationship of platelets to fibrin formation. William 
Osier working at University College also used this technique and in 1874 
submitted a paper entitled 'An account of Certain Organisms Occurring in 
the Liquor Sanguinus' to the Royal Society. In this paper he reviewed 
previous work and gave a detailed account of individual platelets. In 
studies of blood vessels in loose connective tissue of the rat he described 
individual platelets with no tendency to stick together, but never 
granular masses. However if blood was taken from the animal granular 
masses formed. He also studied the formation of granular masses and 
observed the formation of pseudopods at the periphery of the mass associated 
with fibrin production. Giulio Bizzozero who was Professor of General 
Pathology in Turin made important contributions to the study of thrombosis 
and published in 1882 'On a New Element of Mammalian Blood and Part it 
Plays in the Production of Thrombi and Coagulation Generally'. In addition 
to repeating earlier work he showed that it was platelets that formed the
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first stage of thrombosis and demonstrated their relationship to coagulation, 
In 1881 Osier observed that the white thrombus on an atheromatous plaque 
consisted entirely of platelets and in 1885 ICurtStKimmelbusch described 
the morphological changes occurring on contact of platelets with foreign 
surfaces or a damaged vessel and the increased stickiness of individual 
platelets and he believed that these events preceded fibrin formation.
In 1906 Wright determined the relationship of platelets to the mekakaryocyte 
(reviewed by Robb-Smith, 1967).
These findings in the latter half of the nineteenth century reflected 
the increasing power of the optical microscope and subsequent progress in 
this century has depended on the application of the electron microscope to 
the analysis of platelet ultrastructure (reviewed by White e t  a t , 1981); 
increased understanding of platelet biochemistry (reviewed by Gordon, 1981); 
the ability to measure platelet function (Born, 1962); appreciation of the 
importance of arachidonic acid metabolites in platelets and platelet vessel 
wall interactions (reviewed by Moncada, 1983) and the relationship of 
platelets to atherogenesis (Ross and Glomset, 1976).
Fiatelet Structure
Platelet structure and its relationship to platelet function has been 
given tremendous impetus through the application of electronmicroscopy 
to the study of platelet anatomy and the development of techniques for 
isolation of physiologically active platelets and their preservation for 
ultrastructural study (David-Ferreira, 1964; White, 1979). The subject 
has been reviewed (White e t  a t , 1981) and will be briefly described here 
(see Figure 1 ). Platelet anatomy is generally considered in four zones 
for simplicity and also to relate structural to physiological activities.
. The peripheral zone comprises the platelet cell surface, the surface 







Figure 1. Platelet Ultrastructure (White et  al^ 1981).
EC, exterior coat; CM, trilaminar unit membrane; SMF, sub-membrane
filaments; CS, surface connected cannilicular system; MT, microtubules ;
Gly, glycogen; M, mitochondria; G, granules; DB, dense .bodies ; DTS, 
dense tubular system.
35.
unit membrane and the sub-membrane region. The glycocalyx of platelets 
is thicker and more dense than surface coats of other blood cells and is 
rich in glycoproteins (Berndt and Phillips, 1981) which is not surprising 
bearing in mind the number of receptor functions and transport mechanisms 
active at the platelet surface. The identification and analysis of this 
large number of glycoproteins has depended on the use of a large number 
of surface labeling probes such as lactoperoxidase catalysed iodination 
(Phillips, 1972) and transglutaminase (Okumura and Jamieson, 1976) which 
label amino acids and galactose oxidase which labels carbohydrate (Phillips 
and Agin, 1977 ). In addition to these enzyme catalyzed labelling techniques 
membrane impermeable reagents have been used including C^^^Hglp-chloro- 
mercuribenzene sulphonate (Nachman and Ferris, 1972), diazotized 
diiodosulphanilic acid (George e t 1977), pyridoxal phosphate with 
subsequent reduction of the Schiff's base with C^H] sodium borohydride 
(McGregor e t  aly 1979) and the oxidation of sialic acid residues with 
sodium metaperiodate and reduction with sodium borohydride (Gahmberg
and Andersson, 1977). Following the use of these labelling techniques 
various electophoretic analyses has enabled the separation and identification 
of the labeled proteins including one dimensional SDS-polyacrylamide gel 
electrophoresis (Jenkins e t  aly 1980), two dimensional gel analysis 
(O’Farrell, 1975), two dimensional non-reduced - reduced SDS -polyacrylamide 
gel electrophoresis (Phillips and Agin, 1977b) and crossed immunoelectro- 
phoresis (Hagen e t  dty 1980), Although these techniques have identified 
many glycoproteins on the platelet surface (> 30) there are some notably 
Ib Ilb III and IV which are present in high concentration and their 
functional roles are emerging as will be described later.
The trilaminar unit membrane of the peripheral zone which provides the 
physiochemical separation between extracellular and intracellular 
constituents has important components including the sodium/potassium ATPase.
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There do not appear to be major differences between the platelet membrane 
and that of other blood cells. However intercalated particles (probably 
trans-membrane proteins) appear to be fewer in number (White, 1979).
The membrane lipids, important as sources of arachidonic acid for the 
cyclo-oxygenase reaction are distributed assymetrically with sphingomyelin 
and phosphatidyl choline on the outside and phosphatidyl inositol, 
phosphotidyl ethanolami ne and phosphatidylserine on the inner surface 
(Schick, 1979). The sub-membrane region contains a regular system of 
filamentous elements (White, 1969) which can be seen lateral to the 
circumferential band of microtubules in discoid platelets (Zucker- 
Franklin, 1970). These filaments which are in close association with 
the cell membrane may be concerned with the maintenance of platelet shape 
and in pseudopod formation in conjunction with actin binding protein and 
a-actinin (Lucas e t  aly 1976; Schollmeyer e t  dty 1978).
The so-called sol-gel zone of platelets contains the important micro­
tubules and microfilaments. Microtubules of which tubulin is the major 
protein constituent are located in a circumferential band in the equatorial 
plane just under the cell wall in discoid platelets, which suggests that 
they may be important in maintenance of the platelet cytoskeleton. In 
addition, factors (such as chilling or exposure to agents like colchicine 
and vinca alkaloids which disrupt or prevent formation of microtubules) 
which produce loss of the discoid shape of platelets are associated with 
loss of the band of microtubules (White and Krivit, 1967; White, 1968).
In addition microtubules have a role in platelet contraction when platelets 
are activated, but depolymerization of the tubules does not affect the 
ability of platelets to contract and cause clot retraction (White, 1969b). 
However there was a transient decrease in polymerized tubulin a few seconds 
after platelet activation induced by a variety of aggregatory agonists which 
recovered after 1-4 min (Steiner and Ikeda, 1979) and following platelet
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activation microtubules were observed in a tight band around centrally 
grouped organelles (White, 1968b). Therefore microtubules may be involved 
in internal alignment of platelet organelles prior to the release reaction 
and furthermore may help govern the degree of response to circulating 
agonists (White e t  dly 1981),
The second system of fibres in the sol-gel zone of platelets comprises 
the microfilaments (White, 1971). They resemble actin filaments found 
in other contractile cells such as muscle and platelet actin has a hundred­
fold excess over platelet myosin (Pollard, 1975). The microfilament system 
provides the contractile capacity for the release reaction seen in activated
platelets (Adelstein and Pollard, 1978). Cohen e t  aZ (1980) have postulated 
that the actin filaments are anchored to the platelet membrane by a-actinin 
(glycoprotein III) a trans-membrane protein (Gerrard e t  dty 1979). The 
actin filaments extend into the cytoplasm from this point and form long 
filaments orientated concentrically around the platelet granules. The 
myosin filaments would interdigitate between the actin filaments in 
opposite directions and help to push the platelet granules into the centre 
of the platelet for release into the surface connected open canalicular 
system. ~ »
The platelet organelle zone is rich in several types of organelle. In 
addition to mitochondria platelet cytoplasm contains numerous granules and
dense bodies which have been distinguished by density, ultrastructural 
studies and biochemical content. The dense bodies (- 250-300 nm) so- 
called because of the electron dense opaque internal content when visualized 
with the electronmicroscope are the storage sites for 5-hydroxytryptamine, 
adenine nucleotides, calcium and pyrophosphate (Holmsen and Weiss, 1979). 
Alpha-granules are the most numerous of platelet organelles and they have 
a variety of densities and staining characteristics. These granules 
(300-500 nm) store many proteins some of which are specific to platelets
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such as platelet factor 4, 3~thromboglobulin, low affinity platelet 
factor 4 and platelet derived growth factor. In addition alpha-granules 
contain proteins which are found in other cells and plasma such as 
fibrinogen, fibronectin, albumin and factor Vlll-related antigen. It 
is probable that there are different types of alpha-granule with different 
granular contents which may be released in different situations (Kaplan, 
1981), Platelets also possess a variety of lysosomal enzyme storage 
organelles containing acid hydrolases including ^-glucuronidase, 
3-N-acetylglucosaminidase and 3~galactosidase (Holmsen, 1975).
Platelets contain two important membrane systems the surface-connected 
open canalicular system and the dense tubular system. The canalicular 
system consists of tortuous invaginations of the platelet wall running 
through the platelet cytoplasm and therefore greatly increasing the total 
surface area of platelet/plasma contact (Behnke, 1970). This system 
remains patent despite platelet contraction, adhesion and aggregation 
and probably serves for the release of the contents of the platelet 
storage granules to plasma (White, 1973). The dense tubular system which 
probably represents residual smooth endoplasmic reticulum is discrete from 
the open canalicular system (Behnke, 1970) but forms very close relationships 
with it in certain areas of the cytoplasm (White, 1972). An important 
physiologic role for the dense tubular system is calcium sequestration 
through the activity of the calcium/magnesium ATPase (Cutler e t  dty 1978) 
as will be discussed later.
Platelet Physiology
Haemostasis
A series of complex reactions involving the vessel wall, plasma 
proteins and blood platelets occur to reduce the loss of blood following 
injury to the vasculature. Platelets contribute to these complex reactions
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in three main ways. They adhere to exposed collagen and form a physical 
plug to occlude the wound; they release active substances from their 
secretory granules which help to consolidate the initial platelet plug; 
they play an important role in interacting with the coagulation system 
and certain intrinsic coagulation reactions occur preferentially on the 
platelet surface. The process of platelet plug formation has been 
reviewed by Sixma and Wester (1977), Macroscopically observations of 
haemostatic plug formation have been made in animal models particularly 
the hamster cheek pouch and the rabbit mesentery. Whereas transection 
of a capillary causes no bleeding, arterial transection results in 
contraction, retraction and brisk bleeding. Contraction is probably 
only important in the larger arteries and no contraction or retraction 
is seen when a vein is transected. Immediately following transection 
of the blood vessel there is accumulation of platelets on the exposed 
connective tissues at the edge of the wound. This is seen as a greyish- 
white accumulation of material which grows and obstructs blood flow. 
Eventually bleeding stops but may restart through channels in the platelet 
plug which are then occluded again. The haemostatic plug protrudes from 
the vessel and the blood behind the plug becomes stagnant.
Histological studies of platelet plug formation have been performed 
in animals and in biopsies of human skin following bleeding time studies 
(Sixma and Wester, 1977; Wester e t  dty 1978; Wester e t  dty 1979). The 
earliest finding is the platelet adhesion to collagen fibres followed 
by aggregation and formation of a platelet plug. There is some fibrin 
formed at the edges of the wound and at the plug periphery but no fibrin 
is seen within the plug for about 15-30 min. In the first minute
of the plug formation the platelets retain their granules and remain 
loosely packed. However subsequently they become more closely packed 
and release their granules^and the plug becomes a dense mass of inter-
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digitated platelets. The major changes to the plugs in the hours following 
transection of the vessel are that lytic areas initially seen at the edges 
of the plug also develop in its centre and the degranulated platelets 
resemble empty vesicles. The pseudopodia disappear and the platelets 
appear round once more (Wester e t  dty 1979). In addition there is 
increased fibrin formation with masses of fibrin between the platelets 
eventually forming a network of thick strands after 24 h (Hovig e t  d l y
1968). The platelet plays an important role in interacting with the 
coagulation system and certain intrinsic coagulation reactions occur 
preferentially on the platelet surface which appears to protect coagulation 
enzymes from inactivation by plasma proteinases and localises fibrin 
formation within and around the platelet plug (Walsh, 1981). Fibrin 
deposition strengthens the platelet plug and the haemostatic barrier is 
complete. There is also infiltration of polymorphonuclear and mononuclear 
cells in the wound and sometimes in the plug itself and interestingly along 
the blood vessel near the wound (Wester e t  d t y  1979).
As can be seen from the above description the formation of the 
haemostatic plug or "primary haemostasis" involves many properties of 
platelets including adhesion, aggregation, degranulation and release 
reaction and these platelet properties will be briefly described.
Platelet Adhesion
It is thought that the platelet is necessary for the maintenance of 
normal vascular integrity in that patients with thrombocytopaenia show a 
generalised haemorrhagic tendency and bruising when the platelet count 
falls below about 50 x 10^/1, spontaneous bruising and more severe bleeding 
being possible as the platelet count falls below 20 x 10^/1. In addition 
haemorrhage can also occur due to qualitative platelet defects such as 
essential thrombocythaemia • (McClure e t  d t y  1966). The mechanism for the
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maintenance of this functional integrity is yet to be established but 
presumably would involve platelet adhesion to the endothelium.
Platelets do not usually adhere to normal endothelium but the reasons 
why normal endothelium is inert with respect to stimulating platelet 
adhesion and aggregation is not fully understood (Shattil and Bennett,
1981). However Moncada e t  a i (1976) demonstrated that endothelial cells 
were capable of producing a potent anti-platelet aggregatory agent and it 
was subsequently suggested that continuous production of this substance 
now called prostacyclin explained the apparent protection against adhesion 
and aggregation conferred by the normal endothelium (Moncada e t  dly 1976; 
Moncada and Vane, 1979). The ability of vascular endothelium to inhibit 
platelet aggregation had been previously noted (Saba and Mason, 1974) 
but the presence of an ADP-ase enzyme had been suggested to explain this 
observation (Heyns e t  aly 1974). Subsequent experimental work has cast 
doubt on this suggestion. For instance in the rabbit, doses of aspirin 
sufficient to inhibit prostacyclin production does not lead to platelet 
adhesion to intact endothelium (Dejana e t  aly 1980). In addition several 
studies have demonstrated that the amounts of prostacyclin normally found 
in the circulation are probably too low to have an appreciable effect on 
platelets (Steer e t d l y  1980; Haslam and McClenaghan, 1981; Greaves and 
Preston, 1982) and endothelial cells in culture produce little prostacyclin 
unless stimulated by thrombin for instance (Weksler e t  aly 1977).
Platelets will adhere to a variety of surfaces, both artificial and 
naturally occurring, the most important 171 vi/OO is the adhesion to collagen 
which occurs when the blood vessel endothelium is damaged. This will 
be discussed in a later section of this thesis.
Platelet Aggregation
Platelet aggregation or platelet-platelet stickiness can be regarded 
as a special case of platelet adhesion and follows adhesion of platelets
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to injured surfaces. Normally,, as has been described, aggregation is 
apparent in experimental wounds within seconds. Aggregation has been 
studied 'in vitro more than any other platelet activity because of the 
development of a simple photometric method for its measurement (Born, 1962) 
This is based on the observation that the optical density of stirred 
platelet-rich plasma (PRP) falls as aggregates develop and returns to 
normal as they disperse. Aggregation In vitro which is an active process 
(Vargaftig et dly 1981) is dependent on pH, temperature, mechanical 
stirring, calcium ion concentration, the concentration of platelets in 
the PRP and the time elapsed between the performance of the aggregation 
tests and the preparation of the PRP (Mills, 1981). Numerous natural 
and artificial substances are capable of causing platelet aggregation 
Table 3 ) and depending on the nature of the aggregating agent and its 
concentration, aggregation may be reversible or irreversible and have 
one or two phases.
Adenosine diphosphate (ADP) was the first agent discovered that caused 
aggregation (Gaarder et d l y  1961). ADP induces aggregation directly and 
leads to the platelet release reaction (Macmillan, 1966). A single phase 
of aggregation followed by rapid disaggregation is seen with low 
concentrations of ADP. At threshold concentrations a second phase caused 
by ADP release from the platelets is seen and at high concentrations a 
single phase with irreversible aggregation is observed (Hardisty et a l y
1970). Primary ADP-induced aggregation requires fibrinogen (Niewiarowski 
et al y  1977) which appears to be involved in early transitory interactions 
between platelets (Mustard et a l y  1978). Other plasma protein co-factors, 
possibly adsorbed coagulation factors of the vitamin K dependent group 
may also be required (Miale and Kent, 1975). ADP may play a central role 
in the initiation of physiological platelet aggregation. This nucleotide 
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tissue and erythrocytes (Bergvist and Arfos, 1976).
At low concentrations of collagen platelet aggregation is dependent 
on the release of arachidonic acid from platelet membrane phospholipid 
and the subsequent metabolism of arachidonic acid via the prostaglandin 
pathway (Packham, 1976). However at higher concentrations collagen also
causes release of ADP from platelet granules and this is independent of
the prostaglandin pathway. For collagen to promote platelet aggregation
it must possess its triple helical structure and must be present as
fibrillar collagen (Zucker and Borelli, 1962).
Adrenaline induces a Mphasic response when added to PRP (Macmillan, 
1966). The first wave of aggregation induced by adrenaline is associated 
with uptake of calcium by platelets and it has
been suggested that a localized flux of calcium into the platelet plasma 
membrane enables the platelets to stick together (Gerrard e t  dly 1981). 
Unlike other aggregating agents (ADP, collagen and thrombin) adrenaline 
does not cause initial platelet shape change (seen as a transient increase 
in optical density of PRP). These other aggregating agents which cause 
shape change before platelet-platelet aggregation release calcium initially 
from an intracellular structure probably the dense tubular system so that 
there is an elevation in cytoplasmic calcium before plasma membrane calcium 
is altered (Gerrard e t  d l y  1981).
The mechanisms by which platelet sticks to platelet during aggregation 
are not fully understood. However, extracellular calcium is necessary 
and there is considerable evidence particularly from studies of 
thrombasthénie platelets that the platelet surface glycoproteins lib and 111 
are involved (Nurden and Caen, 1974; Nurden and Caen, 1975; Phillips and 
Agin, 1977). More recently, fibrinogen has been strongly implicated in 
platelet/platelet interactions. Platelets activated by thrombin were 
found to produce haemagglutinin activity with fixed bovine erythrocytes
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(Gartner e t  dly 1978) and subsequently the same group have shown that this 
agglutinin is bound to platelet membranes and appears in the incubation 
fluid following platelet activation by thrombin (Gartner e t  dly 1980).
It is highly likely that this agglutinin is fibrinogen (Gartner e t  dly 
1980; Bemdt and Phillips, 1981). Indeed the role of fibrinogen in 
platelet aggregation has been recognised for many years (Born and Cross,
1964; Brinkhous e t  aly 1965). ADP stimulated platelets exhibit increased 
fibrinogen binding (Mustard e t  aly 1978) and the features of the binding 
suggested a fibrinogen receptor on the platelet membrane which required 
extracellular calcium (Bennett and Vilaire, 1979; Peerschke e t  aly 1980).
Platelet Release Reaction
The release of platelet-derived material and the profound biochemical 
and morphological changes that occur after platelet stimulation have been 
termed the platelet release reaction (Grette, 1962). On stimulation 
platelets release their dense bodies, alpha granules and lysosome-like 
granules (see Table 4 ) but the integrity of the membrane structures, 
cytoplasm and mitochondria is preserved. Grette performed his experiments 
in porcine platelets stimulated by thrombin but subsequently many substances 
(secretagogues) have been found to provoke platelet aggregation. ADP, 
adrenaline and collagen as well as thrombin provoked release of 
5-hydroxytryptamine and nucleotides from platelets (Mills e t  aly 1968).
In addition immune complexes (Humphrey and Jaques, 1955) arachidonic acid 
(Kaplan et  aly 1979) and its metabolites prostaglandin endoperoxides 
and thromboxane A^ (Hamberg et  aly 1975) cause platelet release. More 
recently the degranulating action of platelet — activating factor has been 
demonstrated (Chignard e t  aly 1979; MaManus e t  aly 1979). Some 
secretagogues (e.g. ADP) stimulate the release of certain granules (dense 
bodies, some alpha granules but not the lysosomal granules) whereas thrombin
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Table 4. Subcellular localization of secreted platelet constituents
Alpha-granules Dense granules Lysosomes











stimulates secretion of all types of granule including lysosomes (Holmsen, 
1977). In addition to these ’physiological stimuli’ many ’non-physiological’ 
stimuli stimulate platelet degranulation including calcium ionophores 
(Gerrard e t  dly 1974), lectins (Greenberg and Jamieson, 1974) and latex 
and viral particles (Holmsen, 1977). As reviewed by Skaer (1981) it is 
probable that there are many different types of granule. In addition 
the response to various secretagogues in terms of which granules are 
released and to what extent varies which suggests that platelets must 
possess very sophisticated intracellular control mechanisms.
Dense body contents are discharged through the platelet surface 
membrane (Skaer, 1981) and this occurs from between 4 sec and 3 min 
after addition of the secretagogue. Mobilisation of the internal
calcium occurs after 0.75 - 1.8 sec following the addition of thrombin 
(Feinstein, 1980). Therefore the release of intracellular membrane bound 
calcium precedes the onset of the stimulus induced degranulation. A 
further factor involved in the stimulus to degranulation may be the 
breakdown of phosphatidylinositol with the accumulation of diglyceride 
j(l-stearoyl,2-arachidonyl diglyceride). Diglyceride levels after thrombin 
stimulation increase 30-fold after 15 sec (Rittenhouse-Simmons,
1979). The diglyceride may be important in promoting membrane fusion 
of the dense body granule with the platelet surface membrane and also as 
a substrate for the formation of prostaglandin endoperoxides and 
thromboxane A^ which are powerful degranulation stimuli (Bell et  aly 1979).
In addition the actual breakdown of the membrane polyphosphoinosides by 
calcium stimulated enzymes may promote degranulation as they have highly 
charged polar head groups which would tend to impede membrane fusion 
(Allan and Michell, 1979).
As has been seen the platelet alpha-granules contain a large number 
of proteins and are very numerous in the platelet cytoplasm. For instance
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alpha-granule fibrinogen forms approximately 10% of total platelet protein 
(Holmsen and Wens, 1979). Not all alpha-granules may respond in the 
same way to secretory stimuli in that Zucker e t  d l (1979) who demonstrated 
that over 80% of platelet factor VIII related antigen was present in the 
alpha-granules could only demonstrate the release of 30% of this in response 
to stimulation with collagen. Similar findings have also been described 
for fibronectin (Ginsberg e t  aly 1979). Although there are several 
possible explanations for these findings as reviewed by Skaer (1981) it 
is possible that some alpha-granules may remain refractory to secretory 
stimuli.
The contents of the alpha-granules unlike those of the dense bodies 
are discharged into the open canalicular system. Alpha-granule nucleoids 
have been demonstrated by electronmicroscopic studies in the canalicular 
system (White, 1974) and it is likely that normal secretion involves not 
only fusion of these granules with the canalicular system but in addition 
platelet contraction, the evidence for this coming from the use of 
differing secretagogues (Gerrard e t  aly 1974).
Platelet Prostaglandin Metabolism
Over recent years there has been increasing interest in these 
widely distributed and biologically important compounds and their importance 
in platelet biochemistry and platelet/vessel wall interactions has been 
emphasized.
The prostaglandins and thromboxanes are 
produced from certain 20-carbon atom polyunsaturated fatty acids with 
varying degrees of unsaturation. The most abundant of these acids in 
human tissue is arachidonic acid (Crawford, 1983). Most arachidonic acid 
is esterified in membrane phospholipid complexes and in order to act as 
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Figure 2. The prostaglandin pathway (from Moncada, 1983), 
Arachidonic acid, AA; prostglandin, PG; 
thromboxane, TX.
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acid must be liberated by the action of phospholipase . The activity 
of this membrane enzyme thus provides the first control step in the 
prostaglandin pathway by limiting the availability of arachidonic acid 
substrate.
Free arachidonic acid is then acted upon by the system of microsomal 
enzymes known as prostaglandin synthetase which is composed of cyclo- 
oxygenase and peroxidase activities. In the presence of molecular oxygen, 
the cyclo-oxygenase activity converts arachidonic acid to a 15-hydroperoxide 
endoperoxide known as prostaglandin Gg which is then converted by the 
peroxidase activity to a 15-hydroxy endoperoxide known as prostaglandin Hg 
(Lands, 1979)(see Figure 2 ). Prostaglandin is an unstable compound 
which has a half-life of approximately 5 min (van Dorp e t  a l , 1978)
and once formed is rapidly transformed either enzymatically or non-enzymatically 
to the classical prostaglandins, prostaglandin , Eg and Fg^ (Nugteren
and Hazelhof, 1973; Miyamoto e t  a l , 1974; van Dorp e t  a l , 1978). Most 
tissues are capable of synthesizing these unstable endoperoxides and 
prostaglandins and it is further products of the prostaglandin pathway 
which determine the biological effects observed in different tissues.
The synthesis of the prostaglandins Eg and Fg^ was demonstrated in platelets 
stimulated with thrombin by Smith and Willis (1971). These authors found 
that oral administration of aspirin was associated with inhibition of 
platelet prostaglandin synthesis and suggested that this finding might 
explain the known effects of aspirin in inhibiting the platelet release 
reaction (O'Brien, 1968) and in prolonging the bleeding time (Quick, 1966). 
However it was difficult to accept this concept as the prostaglandins 
measured were not pro-aggregatory. This was resolved a short time later 
when an unstable product of a short term incubation of arachidonic acid 
with cyclo-oxygenase prepared from the vesicular gland of sheep was found 
to induce platelet aggregation (Willis and Kuhn, 1973). This product was
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subsequently found to be prostaglandin Hg and the unstable endoperoxides 
prostaglandin Gg and prostaglandin Hg were found to be released during 
platelet aggregation (Hamberg e t  a t , 1974). In addition when these 
compounds were added to platelets they provoked aggregation (Hamberg e t  
a t , 1974; Hamber and Samuelsson, 1974). Platelet aggregation induced by 
endoperoxides appeared to be greater than that which could be accounted 
for by the endoperoxides alone and Hamberg e t  a t (1975) were able to 
demonstrate that in platelets, endoperoxides are further metabolised to 
a very unstable compound, thromboxane Ag. Thromboxane Ag has a half-life 
of 30 sec at body temperature and degrades spontaneously to the stable 
metabolite thromboxane Bg (Hamberg e t  a t , 1975). Subsequently the 
microsomal fractions of human platelets have been shown to contain an 
enzyme which converts the endoperoxides, prostaglandin Gg and Hg to 
thromboxane Ag and the enzyme has been designated thromboxane synthetase 
(Needleman e t  a t , 1976). Thromboxane synthetase also catalyses the 
conversion of prostaglandin Hg to a C-17 hydroxy acid known as 12-hydroxy- 
5.8.10-hepta-decatrienoic acid and malondialdehyde (Diczfalusy and 
Hammarstrom, 1977). However prostaglandin Hg conversion to these compounds 
may also occur non-enzymatically (van Dorp e t  a t , 1978). It appears from 
experiments in which platelet membrane fractions have been separated that 
thromboxane synthesis is associated with intracellular membranes known as 
dense tubular membranes (Carey e t  a t , 1982).
Platelets can also metabolise archidonic acid by a lipoxygenase enzyme 
system to yield a variety of hydroxy acids via their respective hydroperoxide 
intermediates (Hamberg and Sammuelson, 1974; Nugteren, 1975). The 
biological activity of these compounds remains to be determined. However 
12-L-hydroperoxy 5,8,10,14-eicosatetraenoic acid may inhibit prostacyclin 
synthetase and cyclco-oxygenase (Siegal e t  a t , 1979).
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In 1976, a new relatively inactive arachidonic acid metabolite 
characterised as 6-oxo-prostaglandin was isolated from several tissues 
including guinea-pig lung (Dawsen e t  a t , 1976) and rat stomach (Pace- 
Asciak, 1976). In the same year Moncada e t  a t (1976) reported the presence 
of an enzyme in aortic tissue which converted prostaglandin endoperoxides 
to a potent unstable inhibitor of platelet aggregation. This factor also 
relaxed arterial smooth muscle and was named prostaglandin X (Moncada e t  a t ,
1976). Prostaglandin X rapidly lost activity in neutral and acidic media 
with the formation of a relatively inert substance subsequently identified 
as 6-oxo-prostaglandin F^^ and prostaglandin X was identified as 9-deoxy-6, 
9-epoxy-A^-prostaglandin F^^ and renamed prostacyclin (Johnson e t  a t , 1976). 
The microsomal enzyme converting prostaglandin Hg to prostacyclin was named 
prostacyclin synthetase and prostacyclin was found to be the major product 
of arachidonic acid in the walls of arteries and veins in several animal 
species and man (Moncada and Vane, 1978). However prostacyclin synthetase 
although present in many tissues is not present in platelets (Moncada and 
Vane, 1979).
Thromboxane Ag is a more powerful pro-aggregatory substance in platelets 
than the endoperoxides and it has been proposed that it is the arachidonic 
acid petabolite that mediates platelet aggregation and the release reaction 
(Hamberg e t  a t , 1975). Whether platelet endoperoxides have a pro-aggregatory 
role in their own right or only when converted to thromboxane Ag has been 
the subject of many studies (Bunting e t  a t , 1983). However from experiments 
using thromboxane synthetase inhibitors it appears that when platelets are 
activated and the prostaglandin cascade is triggered by release of 
endogenous arachidonic acid then the endoperoxides generated exert their 
pro-aggregatory effects by their conversion to the more potent compound 
thromboxane Ag. However when thromboxane generation is suppressed it is 
probably that endoperoxides can be pro-aggregatory themselves (Bunting e t
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a l , 1983).
It has been proposed that endoperoxides and thromboxane Ag activate 
platelets by acting as calcium ionophores hence mobilising intracellular 
free calcium (Gerrard e t  a l , 1978). However all prostaglandins that 
induce platelet aggregation cause a monophasic or reversible 'primary* 
response at low concentrations and a monophasic irreversible 'secondary' 
response at high concentrations. In this way the activation of platelets 
by prostaglandins resembles that produced by ADP and adrenaline. This 
is unlike the activation induced by the powerful stimulus of calcium 
ionophores in that prostaglandins induce platelet dense body secretion 
and alpha-granule secretion but not secretion of lysosomal hydrolases 
(MacIntyre, 1979). For this reason and others (reviewed by MacIntyre,
1981) including studies with antagonists, desensitisation experiments 
and measurement of calcium ionophore activity it is thought that platelet 
activation by prostaglandins and thromboxanes is receptor-mediated although 
a suitable radio-labelled ligand is not available for definitive demonstration 
(MacIntyre, 1981).
Recently Defreyn e t  a l (1981) have demonstrated a deficiency of 
thromboxane formation and platelet aggregation in platelets from a patient 
with a familial bleeding tendency thus emphasizing the importance of 
thromboxane production in the physiology of platelet function.
Thromboxane Ag is a powerful vasoactive compound and the activity of 
the rabbit aorta-contracting substance released from sensitized guinea-pig 
lungs described by Piper and Vane (1969) is accounted for by this substance 
(Hamberg e t  a l , 1975). Because of its highly unstable nature various 
thromboxane Ag generating systems have to be used in order to study its 
vasoactive properties. Using these techniques it has been shown that 
thromboxane Ag is a potent contractor of isolated vessel segments from 
several species including coronary arteries from pig and cattle, human
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umbilical artery and rabbit aorta (Moncada and Vane, 1979). In addition 
strips of bovine cerebral conductance arteries and human basilar arteries 
contract with thromboxane Ag (Ellis e t  d l , 1979; Boullin e t  a t , 1979).
The effect of thromboxane Ag on differing vascular preparations has also 
been studied tn vtvo using thromboxane synthesized in v t t r o by incubations 
of endoperoxide with platelet microsomes. Using this technique Dusting 
e t  a t (1978) were able to show short term vasoconstriction in femoral and 
vascular beds of the dog following injection of the thromboxane close to 
the vessels.
Prostacyclin has powerful metabolic effects on blood platelets. It has 
the most potent effect of the naturally occurring prostaglandins in inhibiting 
platelet aggregation being 30-40 times more potent than prostaglandin E ̂ 
and 10 times more potent than prostaglandin Dg in  v i t r o (Moncada e t  a t ,
J976; Gryglewski e t  a t , 1976). Prostacyclin can also bring about 
disaggregation of platelet aggregates i n  v i t r o (Moncada e t  a t , 1976;
Ubatuba e t  a t , 1979). In addition using animal models, prostacyclin 
applied locally has been shown to inhibit thrombus formation in response 
to ADP in the hamster cheek pouch microcirculation (Higgs e t  a t , 1977) 
and given systemically, prostacyclin inhibited thrombus formation induced 
electrically in rabbit carotid artery (Ubatuba e t  a t , 1979). Similar 
findings were observed with prostacyclin either applied locally or given 
systemically in the coronary artery of dog (Aiken e t  a t , 1979).
When given systemically prostacyclin protected against sudden death 
(secondary to platelet aggregation) in the rabbit following intravenous 
injection of arachidonic acid (Bayer e t  a t , 1979). Gryglewski e t  a t
(1978) incorporated collagen strips into extrkcorporeal circuits in animals 
and showed that prostacyclin brought about disaggregation of platelet 
aggregates formed on the collagen strips. Similarly prostacyclin inhibited 
platelet aggregation on rabbit sub-endothelium but only prevented platelet
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adhesion at higher doses (Higgs e t  d i , 1978). In man prostacyclin infusion 
inhibited platelet aggregation measured ex vivo at a threshold dosage of 
2 ng/kg/min and with increasing doses there was increased inhibition of 
ADP-induced aggregation (Fitzgerald e t  a t , 1979).
Although platelets cannot synthesize prostacyclin they do possess the 
enzyme 9-hydroxyprostaglandin dehydrogenase (Wong e t  d l , 1980). This 
enzyme can transform 6-oxo-prostaglandin F^^, the stable hydrolysis product 
of prostacyclin into 6-oxo-prostaglandin Ej which does possess anti-aggregating 
effects (Quilley e t  d i , 1980). However the possible biological role of this 
metabolite in platelet function remains to be determined as plasma levels 
of 6-oxo-prostaglandin Ej (measured by gas chromatography, mass spectrometry 
techniques) did not increase following intravenous infusion of prostacyclin 
(Jackson e t  d l , 1982).
The potent inhibitory action of prostacyclin on platelet aggregation 
correlates with its ability to stimulate the platelet adenylate cyclase 
system thus increasing cyclic AMP levels within the cell (Tateson e t  dt,
1977). Stimulation of adenylate cyclase follows binding of prostacyclin 
to a platelet membrane receptor which it shares with prostaglandin Ej but 
is distinct from the prostaglandin receptor (Miller and Gorman, 1979). 
Shepherd e t  d i (1983) have calculated that each human platelet has 4200 
high affinity binding sites for prostacyclin with a dissociation constant 
of 16 nmol. In keeping with its stronger anti-platelet aggregatory effects 
compared to prostaglandin Ej, prostacyclin stimulation of adenylate cyclase 
activity is more potent and more sustained (Gorman e t  a t , 1977). By 
enhancing platelet cyclic AMP levels through its stimulation of adenylate 
cyclase, prostacyclin can reduce cytoplasmic calcium levels which determine 
platelet shape change, aggregation and the release reaction (Kaser- 
Glanzmann e t  a t , 1977). In addition platelet phospholipase (Minkes e t  
a t , 1977) and cyclo-oxygenase (Malmsten e t  a t , 1976) are inhibited by
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the elevated cyclic AMP levels.
Prostacyclin is the major product of arachidonic acid in blood vessels 
(Moncada e t  d i , 1977a) and the synthesis is highest in the intima (Moncada 
e t  a i , 1977). Capillaries also generate prostacyclin (Goehlert e t  a i ,
1981) and studies with cultured cells have demonstrated that it is endothelial 
cells which are the main source (Weksler e t  a i , 1977). Thus when endothelium 
was stripped from rabbit aorta in  vivo prostacyclin production at the luminal 
surface of the vessel was virtually absent in response to arachidonic acid 
and recovery of prostacyclin production was slow over a period of 70 days 
coinciding with the appearance of neo-intimal cells (Eldor e t  a l , 1981).
f
Prostacyclin in contrast to thromboxane A^ produced relaxation in most 
arterial preparations tested in  v i t r o and was a potent vasodilator when 
tested in isolated perfused heart preparations (reviewed by Moncada and 
Vane, 1979). In addition. Dusting e t  a i (1979) demonstrated increased 
blood flow in the coronary arteries of the intact heart in open-chested 
dogs following application of prostacyclin. Prostacyclin is a potent 
vasodilator in the micro-circulation as demonstrated using the hamster 
cheek pouch preparation by Higgs e t  a i (1982) and in the cerebral micro­
circulation of the cat by Ellis e t  a i (1979).
In intact experimental animals prostacyclin has a vasodepressor effect 
and this was observed to an equal degree when injected intravenously or 
intra-arterially (Armstrong e t  a i , 1978). This work suggests that 
prostacyclin is not inactivated in the pulmonary circulation unlike other 
prostaglandins. However the vascular activity of prostacyclin in  vivo  
is very short-lived and is less than its chemical half-life at physiological 
temperature and pH (i.e. < 3 min). This suggests that biological
inactivation takes place very rapidly in  vivo and most metabolites of 
prostacyclin have little vasodepressor activity apart from 6-oxo- 
prostaglandin Ej (reviewed by Whittle and Moncada, 1983).
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Platelets, Thrombosis and Atherogenesis 
Thrombosis
Platelets are undoubtedly involved in the final occlusion of atheromatous 
arteries and form the major component (the "white head" of aggregated 
platelets) of the occlusive thrombus (Davies and Thomas, 1981). This 
sudden and often catastrophic event is most likely precipitated by fissuring 
of an underlying atheromatous plaque as detailed analysis of obstructed 
coronary arteries at post-mortem invariably show that the thrombus is found 
in association with haemorrhage into a plaque (Chapman, 1965; Constantinides,
1966 and Friedman, 1970). In addition to their apparent central role in 
the pathogenesis of the arterial thrombus increasing interest has focussed 
on platelets and the coronary microcirculation with the finding of platelet 
aggregates in the coronary microcirculation in some cases of sudden cardiac 
death (Haerem, 1972; El-Naraghi and Genton, 1980). These findings have 
stimulated an increasing amount of research into the mechanisms involved 
yet the pathogenesis of thrombus formation remains to be clarified.
Certainly platelets do not normally adhere to arterial endothelium if it 
is undamaged but the explanation for this antithrombotic property of intact 
endothelium remains obscure. Following the discovery of prostacyclin it 
was suggested that endothelial cell production of this very potent anti­
aggregatory substance might explain this important property (Moncada e t  d i ,  
1977; Moncada and Vane, 1978). However this suggestion has not been 
confirmed experimentally as has been discussed previously. Platelets will 
rapidly adhere and aggregate if the endothelial barrier is breached as has 
been shown in many studies in experimental animals (reviewed by Mustard e t  
a l , 1983) and the platelets adherent to collagen release the contents of 
their alpha and dense granules. Fissuring of an atherosclerotic plaque 
would also expose collagen fibres and the adhering platelets could release
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agents such as thromboxane and ADP which would rapidly lead to adhesion 
and aggregation of more platelets and growth of the thrombus. In addition 
prostacyclin generation is probably reduced in the region of the atherosclerotic 
plaque possibly due to the high content of lipid peroxides in advanced 
atherosclerotic lesions (Glavind e t  a l , 1952) as it is known that fatty 
acid peroxides inhibit prostacyclin generation (Moncada e t  a l , 1976; Salmon 
e t  a l , 1978). Thus Larrue e t  a l (1980) demonstrated that the production 
of prostacyclin by cultured smooth muscle cells obtained from atherosclerotic 
plaques of the experimental atherosclerotic rabbit consistently produced less 
prostacyclin when compared to control cells. Furthermore prostacyclin 
production measured by bioassay and 6-oxo prostaglandin F^^ concentrations 
was reduced in perfused heart preparations from atherosclerotic rabbits 
(Dembinska-Kiec e t  a l , 1977). Similarly prostacyclin production in 
human atherosclerotic tissue appears to be reduced, Sinzinger e t  a l
(1979) demonstrated decreased prostacyclin generation from atherosclerotic 
tissue compared to normal arterial tissue and could find no difference 
between early and advanced lesions. D*Angelo e t  a l (1978) found no 
prostacyclin generation in atheromatous plaques from 3 subjects. In 
addition to the probable decreased prostacyclin production in the region 
of the atheromatous plaque possibly due to inhibition of prostacyclin 
synthetase by lipid peroxides it is known that certain fatty acid 
hydroperoxides also induce platelet aggregation (Mickel and Horbar, 1974).
Thus diminution of prostacyclin production and stimulation of platelet 
aggregation both mediated by lipid peroxides could contribute to thrombosis 
on atheromatous plaques.
Increased thromboxane A^ production may also contribute to throrabogenesis 
in atherosclerotic vessels. Thus platelet thromboxane A^ production 
(measured as the stable degradation form thromboxane B^) is increased in
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patients with arterial or venous thrombosis (Lagarde and Dechavanne, 1977) 
and myocardial infarction (Szczeklik e t  a i , 1978). Similarly in animal 
models, arterial blood thromboxane levels were increased in rabbits 
made atherosclerotic by cholesterol feeding (Shinamoto e t  a i , 1978) and 
following acute ligation of the coronary artery in dog, high levels of 
thromboxane B^ were found to be associated with cardiac arrhythmias (Coker 
e t  a i , 1981). In addition thromboxane B^ levels were found to be elevated 
in the peripheral blood of patients with Prinzmetal angina (Lewy e t  a i ,
1979; Robertson e t  a i , 1981) and in coronary sinus blood of patients with
unstable angina (Hirsch e t  a i , 1981).
Although the above description of experimental findings would suggest
that exposure of collagen and lipid peroxides due to rupture of the 
atheromatous plaque could be of importance in thrombogenesis together with 
enhanced platelet thromboxane A^ formation and diminished vessel wall 
prostacyclin formation. Born (1983) has questioned this series of events.
He has pointed out that platelet aggregates grow very rapidly and, in 
contrast, although platelet adhesion to collagen is almost instantaneous 
there is a lag period (several seconds) before aggregation proceeds (Wilner 
e t  a i , 1969). In addition mural platelet thrombi can occur during passage 
of anticoagulated blood through artificial extracorporeal systems 
(Richardson e t  a i , 1976) which suggests that under certain circumstances 
collagen or other vessel wall constituents are unnecessary for activation 
of platelets. Born (1983) has assembled evidence to suggest that the 
important trigger to in  vivo thrombogenesis is ADP and that at sites of 
vascular injury enough ADP is released from damaged cells to initiate 
thrombogenesis (Born, 1983).
Whatever the physiological stimulus to platelet aggregation and thrombus
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formation it appears that it is the fissuring of an atheromatous plaque 
often with extrusion of plaque lipid contents which triggers thrombus 
formation (Bouch and Montgomery, 1970). The nature of this obviously very 
important event remains unclear. . However a possible explanation has been 
put forward by Brooke e t  d i (1971) which proposes that softening of the 
atheromatous plaque may be due to the presence of unusual lipids 
(tholesteryl esters of hydroxyoctadecadienoic acid) found in high concentrations 
in ulcerated plaques (Harland e t  a i , 1971) which are thought to produce 
smooth muscle cell necrosis at the base of the plaque.
Atherogenesis
As has been discussed above platelets are a crucial factor in thrombogenesis 
associated with atheromatous arteries. However over recent years the possible 
role of platelets in the early stages of the atheromatous process has 
been emphasized (Ross and Glomset, 1976). Of course the advanced 
atherosclerotic plaque is a very complex structure (Woolf, 1983) but 
the early lesion is very much a process which involves the intima of 
the artery and is characterised by proliferation of smooth muscle cells 
■which have migrated from the media of the artery. The fact that this 
early lesion is intimai suggests a response to a factor or factors in 
the blood and the "response to injury" hypothesis is central to current 
thinking on the atherosclerotic process. It was Virchow in the middle 
of the nineteenth century who first put forward the concept of arterial 
wall injury leading to the development of the atheromatous plaque. In 
the middle of the twentieth century Duguid (1946) emphasized the importance 
of arterial thrombi in the genesis of the plaque and pointed out that it 
was Rokitansky (1844) who first put forward the 'encrustation hypothesis' .
The role of platelets in the process (which has resulted from the work of
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several groups, French, 1966; Chandler and Hand, 1961; Murphy e t  a i , 1962 
and Ross e t  a i , 1974) as put forward by Ross and Glomset (1976) is really 
a bringing together of the Virchow and Rokitansky hypotheses of more than 
a century ago.in that platelets may thpmselves contribute to vessel injury, 
thrombosis and atherogenesis (Mustard e t  a i , 1983).
The functions of the endothelial cells of the arterial intima have been
reviewed by Majno and Joris (1978) who highlighted several important aspects
of endothelial cell physiology including a barrier function to the formed
elements of blood and plasma macromolecules; resistance to platelet thrombi ;
active transport of substances from blood; synthesis of factors involved
in vessel wall/blood interactions and vascular repair processes. Thus
endothelial cells synthesize many elements of their underlying connective
tissue including fibronectin, elastin, collagen, proteoglycans and
microfibrils (Bornstein and Sage, J980; Buonassisi, 1973; Howard e t  a i ,
1976 and Jaffe e t  a i , 1976) which controls vessel wall permeability as
well as stimulating thrombosis following loss or damage to endothelial
cells (Smith e t  a i , 1979). Exchange of macromolecules across the
endothelium involves active vesicle formation, and transendothelial
channels and intercellular clefts (Chien, 1978; Simionescu e t  a i , 1976).
The resistance of intact endothelium to platelet aggregation does not
solely depend on its ability to synthesize prostacyclin as has been
discussed previously. Other factors which may be involved in this
important property are secretion of plasminogen activator (Loskutoff and
Edgington, 1977); a membrane associated ADPase (Lieberman e t  a i , 1977);
the presence of heparin-like membrane proteoglycans (Thorgeirsson and
Robertson, 1978); the ability to take up and degrade vasoactive amines
(Johnson and Erdos, 1977); the uptake and clearance of circulating thrombin
(Lollar and Owen, 1980) and surface charge (Sawryer and Srinivasan, 1973).
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From the above description it can be seen that the endothelial cell
has many important properties and endothelial damage is proposed as the
initial event in the 'response to injury' hypothesis. In the postulated
series of events breach of the endothelial barrier would expose sub-
endothelial smooth muscle cells and connective tissue to plasma constituents
including lipoproteins, platelets and macrophage-type mononuclear cells
(Barker and Ross, 1979). Following endothelial injury, platelets would
adhere to the injured site, form microthrombi and release their granular
contents which include a potent alpha-granule derived mitogen that
stimulates migration and focal proliferation of intimai and medial smooth
muscle cells (Ross and Vogel, 1978). Subsequently there would be synthesis
of collagen, elastin and proteoglycans by smooth muscle cells, intracellular
and extracellular lipid accumulation and thrombosis associated with the
lesion. Support for this sequence of events has come from animal models
of atherosclerosis and studies using cell culture techniques and as Born 
(1983) has pointed out caution is necessary in translating these findings
to the human situation. However there does seem to be considerable
evidence linking platelets to the development of proliferative arterial
intimai lesions following experimental removal of endothelium in animal
experiments either mechanically or chemically (reviewed by Mustard e t  a l ,
1983). In addition the emerging information regarding the properties of 
the platelet-derived growth factor argues for an important role in the 
atherogenic process of this platelet alpha-granule constituent.
Platelet-derived growth factor has been highly purified and appears 
to consist of two polypeptide chains of molecular weight 14000-17000 
covalently joined by disulphide bonds (reviewed by Bowen-Pope and Ross,
1984). Following its purification it has been possible to study the 
biological properties of platelet-derived growth factor. Important
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amongst these properties are its ability to induce cheraotaxis by vascular 
smooth muscle cells (Grotendorst et  a l , 1982; fibroblasts (Seppa e t  a l ,
1982) and monocytes (Deuel e t  a l , 1982); to increase rates of fluid phase 
pinocytosis (Davies and Ross, 1978) and protein synthesis (Owen e t  a l , 1982); 
to increase the number of LDL receptors (Chait e t  a l , 1980) and somatomedin 
receptors (Clemmons e t  a l , 1980) as well as to stimulate proliferation of 
connective tissue cells. It remains to be seen whether cells can respond 
to platelet-derived growth factor i n  vivo and at the moment its role in 
atherogenesis remains speculative but attractive.
As has been discussed the 'response to injury' hypothesis depends on 
initial endothelial injury and little is known about loss of endothelium 
in  vivo either spontaneously or in response to risk factors for 
atherosclerosis. Although endothelial replication is increased in 
response to hypertension or hyperlipidaemia (Florentin e t  a l , 1969;
Schwartz e t  a l , 1980) this does not necessarily imply that the arterial
intima is denuded of endothelium. In addition electron microscopic studies 
have not shown significant areas of denuded intima in early hyperlipidaemia
in animal models despite there being increased endothelial turnover 
(Bondjers e t  a l , 1977 and Taylor e t  a l , 1978). These findings have led 
to the suggestion that altered endothelial function without endothelial 
loss may be important in permitting platelet thrombus formation. In 
this regard Gryglewski e t  a l (1978) showed that prostacyclin formation in 
segments of blood vessel from cholesterol-fed monkeys was reduced. These 
authors, on the basis of these experiments, suggested a primary role for 
prostacyclin deficiency in the development of atherosclerosis in these 
animals. However this suggestion depends on the assumption that prostacyclin 
is continually produced by arterial wall to prevent platelet aggregation.
This assumption is not tenable as it is now recognised that the unstimulated
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output of prostacyclin by blood vessels is low (reviewed by Dolleiy e t d i ,
1983). However factors that reduce the ability of the vascular endothelium 
to produce prostacyclin may impair the ability of the vessel to response 
to vascular injury (Dollery e t  d i , 1983).
Recent work from Faggiotto e t  a i (1984) and Faggiotto and Ross (1984) 
has cast more light on the 'response to injury' hypothesis in cholesterol 
fed monkeys. These workers have emphasized that the initial lesion in 
this model of atherogenesis is the adherence to endothelium of monocytes 
which then appear to migrate into the sub-endothelium, accumulate lipid 
and become lipid-laden macrophages or foam cells. It was only after some 
months that endothelial denudation was observed with platelet mural thrombus 
attached to exposed lipid containing macrophages. These authors postulate 
that in as yet an unexplained way it is the accumulation of these lipid­
laden foam cells in the sub-endothelium that damage the endothelium thus 
allowing the subsequent developments in the formation of the atheromatous 
plaque to proceed.
Platelets and Diabetes Mellitus
Introduction
It has been seen that platelets may have not only a crucial role in 
thrombogenesis but also in the development of the atheromatous plaque.
This has stimulated interest in the possible role of these factors in 
the premature vascular disease both atherosclerosis and microangiopathy, 
seen in subjects with diabetes mellitus. In addition platelet aggregates 
have been observed in some diabetic patients with microangiopathy and in 
experimental animals (Bloodworth e t  a i , 1965) and microvascular thrombi 
strongly suggestive of platelet aggregates have been observed in sural 
nerve biopsies of diabetic patients (Timperly e t  a i , 1975) and in patients
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dying from diabetic ketoacidosis (Timperly e t  a l , 1974). More recently 
thrombi consisting primarily of platelets and fibrin have been observed 
in the retinal microvessels of the experimental rat some months after the 
induction of diabetes (Ishibashi e t  a t , 1981).
However despite the increasing numbers of research communications 
concerned with platelet function in the diabetic there remain many 
conflicting reports and unresolved questions. Many factors contribute 
to this unsatisfactory situation. For instance there is no absolutely 
satisfactory test of platelet function. Many studies have been performed 
using i n  v i t r o tests and it is difficult to be certain as to the relevance 
of these tests to platelet function in  vivo. Platelets are studied in an 
artificial environment and the very process of preparing the platelet sample 
for study may affect the population of platelets studied and their behaviour 
Despite this there is no doubt that the development of the turbidometric 
method for the study of platelet aggregation in  v i t r o (Born, 1962) gave 
tremendous impetus to the study of platelet function. In more recent 
years as understanding of platelet physiology has increased newer tests 
have been applied to the study of platelets from diabetic subjects which 
may be more relevant to platelet function in  vivo." Two of these 
developments, the measurement of platelet-specific proteins as measures 
of i n  vivo platelet activation and release reaction and the impedance 
aggregometer which allows the assessment of platelet aggregation in whole 
blood have been used in this thesis. For convenience these tests together 
with the results of other studies using these tests will be discussed in 
the Discussion section of this thesis.
In recent years the importance of the prostaglandin pathway in platelets 
in relation to platelet aggregation has become apparent and several studies 
have attempted to assess the activity of this pathway in platelets from 
diabetic subjects. In addition the effect of the diabetic state on
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prostacyclin synthesis and the balance between prostacyclin and thromboxane 
has been examined. For convenience, studies of the platelet prostaglandin 
pathway, prostacyclin and thromboxane in diabetes will be described 
along with the results obtained in this thesis in the Discussion section.
Further attempts to estimate platelet function in  v ivo have involved 
isotopic labelling of platelets and measurement of platelet survival.
However these tests also have potential limitations, the study of large 
patient groups is not practical and the results must be interpreted with 
caution.
In addition to problems intrinsic to the methodology of platelet function 
measurement problems also arise from the diabetic groups studied. Many 
of the early studies of platelet function in diabetic subjects failed to 
take into account other factors known to influence platelet function, 
particularly the presene or absence of diabetic vascular complications.
This has led to difficulties in interpretation of the possible sequence 
of events in the development of enhanced platelet reactivity in diabetics.
In other words are observed platelet abnormalities related to the disturbed 
metabolic state of diabetes or are they secondary to the presence of 
vascular disease? More recent studies have attempted to overcome this 
problem by electively studying diabetics free from clinical evidence of 
vascular disease. However it is difficult to be completely sure of the 
absence of vascular disease on clinical grounds alone and for this reason 
some groups have studied platelet function in diabetic children and 
adolescents in whom vascular disease would be unlikely.
Platelet Adhesion Studies
Early studies of platelet function in diabetes used i n  v i t r o tests of 
platelet adhesion. A variety of techniques were used involving glass beads 
or fibres in a column. Anticoagulated blood or PR?
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vas passed through the column at a fixed flow rate and platelet counts were 
performed before and after exposure to these foreign surfaces - the difference 
being the number of platelets adhering. In general these techniques are 
tricky and difficult to reproduce, and conflicting results were reported. 
Whereas increased platelet adhesion was reported in diabetics with evidence 
of macro- and microvascular disease (Mayne e t  d i , 1970) no increase in 
adhesion was found in diabetics with retinopathy (Heath et a 7̂  .1971)..
However the majority of studies did show increased adhesiveness in diabetic 
subjects with (Baldwin e t  a i , 1970; Valdorf-Hansen, 1967; Hellem, 1971) 
and without (Hellem, 1971; Shaw e t  a i , 1967) vascular disease.
Platelet Aggregation
For 'in v i t r o aggregation studies citrated blood is carefully centrifuged 
to produce PRP. Aliquots of PRP are then placed in an aggregometer and 
stirred at 37°C. Various agonists, e.g. ADP, collagen, adrenaline 
and thrombin are then added to the PRP to induce aggregation which is 
measured as a change in optical density.
Studies of in vitro platelet aggregation in diabetics date from the 
late sixties and early seventies. These early studies were performed 
in diabetics with and without clinical evidence of vascular disease.
However as Colwell e t  a i (1983) have pointed out, if enhanced platelet 
aggregation were to contribute to the pathogenesis of diabetic vascular 
disease then evidence of it should be present before the development of 
vascular disease. Later studies have taken care to define the diabetic 
population studied in terms of the presence or absence of complications. 
Increased platelet aggregation has been reported in patients with neuropathy 
(O'Malley e t  a i , 1975), retinopathy (Heath e t  a i , 1971; Bensoussan e t  a i ,
1975) and coronary artery disease (Szirtes, 1970). However conflicting 
findings have appeared. For instance in studies of retinopathy patients
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- the marker most commonly used of microvascular disease - patients exhibited 
enhanced platelet aggregation to the agonists adrenaline and arachidonic 
acid but not to ADP in a report of 25 patients (Creter e t  a i , 1978). On 
the other hand platelet sensitivity to ADP was exaggerated in retinopathy 
patients studied by Khosla e t  a i (1979) and was significantly greater than 
that in diabetics without retinopathy.
The majority of reports of platelet aggregation studies in diabetics 
without clinical evidence of vascular complications have found increased 
aggregation to various agonists particularly ADP and collagen (Sagel e t  
a i , 1975; Halushka e t  a i , 1977; Stuart e t  a i , 1979; Silberbauer e t  a i ,
1981; Halushka e t  a i , 1981; Janka e t  a i , 1981). However the occasional 
study has failed to demonstrate increased platelet aggregation in diabetics 
free of vascular disease (Petersen e t  a i , 1978; Corbella e t  a i , 1979) but 
certainly it would appear from the studies as a whole that platelet 
aggregation is more enhanced in diabetics with complications.
Spontaneous Platelet Aggregation
Several studies have attempted to assess whether there is evidence of 
increased circulating platelet aggregates in diabetic subjects. The 
platelet aggregate ratio as described by Wu and Hoak (1974) depends on 
the ratio of the platelet count performed on PRP derived from blood mixed 
with formalin to that in PRP prepared without formalin. Formalin fixes 
platelet aggregates which would be removed during the centrifugation to 
produce PRP. Therefore the platelet aggregate ratio would be low in the 
presence of circulating platelet aggregates.
It is important to remember that other factors may affect the platelet 
aggregate ratio such as the rate at which blood is drawn through the 
sampling needle (Rohrer e t  a i , 1978). However using this method Davis e t
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d l (1982) demonstrated that a group of 15 insulin dependent diabetics 
without clinical evidence of complications had a significantly reduced 
platelet aggregate ratio of 0.75 ± 0.6 (± SD) compared to 0.91 ±0.11 in 
age- and sex-matched control subjects. No difference in the platelet 
aggregate ratio was found between a group of 15 diabetics diagnosed after 
the age of 30 years (6 treated with insulin), some of whom had vascular 
complications compared to age- and sex-matched controls. No details were 
given of the glycaemic control or other metabolic parameters of the two 
groups of diabetics studied (Davis e t  a t , 1982) and it is difficult to 
account for these findings. ' Dettori e t  a t (1983) assessed the platelet 
aggregate ratio in 92 'adult onset' diabetics and compared the results 
to 50 control subjects of similar age. No differences were observed in 
the diabetic groups as a whole compared to controls. However when the 
patients were divided into those with good control (glycosylated haemoglobin 
< 9%) and bad control (glycosylated haemoglobin > 9%) it was found that 
the group with poor control had a significantly reduced platelet aggregate 
ratio. Along with this there was a highly significant inverse relationship 
between platelet aggregate ratio and glycosylated haemoglobin. No such 
correlation was seen with various parameters of lipid metabolism (Dettori 
e t  a t , 1983). In a further study of the platelet aggregate ratio in 
diabetic subjects Preston e t  a t (1978) found a significant reduction in 
the diabetic group and this was mainly due to those diabetics with evidence 
of microvascular complications.
The above studies have attempted to assess the presence of circulating 
platelet aggregates. Other studies have measured 'spontaneous' platelet 
aggregation in PRP and whole blood in  v i t r o  using a variety of techniques 
but mostly involving agitation by stirring. The platelet aggregates 
formed in this way are fixed with formol. It is difficult to assess the
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significance of this 'spontaneous' platelet aggregation. However the 
phenomenon is unusual in healthy individuals and it is conceivable that 
circulation stresses may have similar effects on platelets i n  vivo. Studies 
of this kind have demonstrated increased 'spontaneous' in  v i t r o platelet 
aggregation in insulin dependent diabetic subjects free from vascular 
disease (Paulsen e t  a t , 1981; Krzywanek and Breddin, 1981; Silberbauer e t  
a l , 1981).
Platelet Survival
Reduced platelet counts have been reported in subjects with non-insulin 
dependent diabetes (Fuller e t  a l , 1979) which could be due to increased 
platelet consumption. However there have been relatively few studies of 
platelet survival in diabetics and those that have been performed have 
involved small numbers. Eight insulin dependent diabetics were studied 
by Ferguson e t  a l (1975) who measured platelet survival using in  vivo 
labelling with C^^Sel-selenomethionine. Using this technique platelet 
survival was found to be reduced in the diabetic subjects and it was 
unlikely that the findings were due to pre-existing vascular disease as 
the subjects studied were reported to be free from vascular disease.
This is of interest as in an earlier study using ^^chromium-labelled 
platelets Abrahamsen (1968) found reduced platelet survival only in 
diabetics with vascular complications. Dassin e t  a l (1978) also used 
^'chromium-labelled platelets to measure platelet survival in diabetics 
in a more recent study. In this study approximately a third of the 
diabetics studied appeared to have increased platelet turnover but this 
finding did not differ significantly from controls. In this study there 
did not appear to be any relationship between the presence of vascular 
complications and platelet survival (Dassin e t  a l , 1978). A recent study
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has attempted to assess the possible relationship between glycaemic control 
and ^'chromium platelet survival (Jones e t  d l , 1981). These authors studied 
platelet survival in 12 diabetics during periods of hyperglycaemia and 
periods of euglycaemia and were unable to demonstrate any differences.
Indeed platelet survival did not differ between diabetics and 6 control 
subjects overall. However 3 of the diabetics did show significantly 
reduced platelet survival and all 3 subjects had retinal disease suggesting 
that the platelet changes were secondary to the presence of vascular 
complications (Jones e t  d l , 1981). The above studies obviously give 
somewhat conflicting results possibly related to the small numbers of 
diabetics studied and the different techniques used. However support 
for the findings of decreased platelet survival due to the diabetic state 
comes from a study in the experimental diabetic rat in which Johnson e t  
<27 ( 198.0) found decreased platelet survival.
Other workers have measured platelet lifespan by determining the 
recovery of platelet malondialdehyde formation (a measure of the 
prostaglandin pathway) following aspirin ingestion (Baton, 1979; Tindall 
e t  d l , 1981). Baton (1979) used this technique to study 12 diabetics 
and 12 control subjects and the diabetics were found to have a faster 
return to normal of malondialdehyde formation suggesting more rapid 
platelet turnover. Similarly Tindall e t  a l (1981) found a significantly 
reduced platelet lifespan in long-standing diabetics (duration > 10 years) 
whether or not microvascular complications were present.
Blatelets and Lipids
In recent years increasing interest has been focussed on lipid platelet 
interactions (Editorial, 1980). It has been seen that platelet-derived 
growth factor has important effects on LDL receptor activity (Chait e t  a l ,  
1980) and it is known that platelets which are unable to synthesize
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cholesterol de novo possess specific LDL receptors (Aviram et  d l , 1980),
In addition lipoproteins have important actions on prostacyclin production. 
Thus LDL appears to inhibit the production of prostacyclin by arterial 
wall as does VLDL whereas HDL stimulates prostacyclin production (Norday 
e t  d l , 1978). In addition animal studies in which atherosclerosis has 
been induced by cholesterol feeding have emphasized concurrent changes in 
platelets. Thus Wu e t  d l (1975) noted increased platelet aggregates 
6 weeks after feeding an atherogenic diet containing 1.2% cholesterol to 
rhesus monkeys. In addition to these findings early studies of platelets 
from hyprcholesterolaemic patients demonstrated enhanced platelet aggregation 
(Carvalho e t  a l , 1974). , For convenience this and other studies of platelet 
function in hyperlipidaemic states will be discussed along with the findings 
reported in this thesis in the Discussion section.
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AIMS
The aims of the studies to be reported in this thesis are to apply 
newer and possibly more physiological tests of platelet function to 
clinically and biochemically well-documented diabetic and hyperlipidaemic 
subjects who are known to be at risk from premature vascular disease.
1. The platelet-specific proteins 3~thromboglobulin and platelet factor 4 
will be measured in platelet-poor plasma in patients with diabetes 
mellitus and age- and sex-matched non-diabetic control subjects.
The diabetics will be carefully examined for the presence or absence 
(as far as possible) of large and small vessel vascular disease so 
that the levels of platelet-specific proteins can be assessed in 
diabetics with and without complications. In addition glycaemic 
control will be determined in the diabetics by measurement of 
glycosylated haemoglobin levels and fasting individual lipid and 
lipoprotein concentrations will be performed. Correlations will be 
sought between platelet-specific protein levels and these measures 
of the metabolic abnormalities in the diabetics.
2. The platelet-specific proteins will be measured in a group of clinically 
and biochemically well-documented hyperlipidaemic subjects compared to 
age- and sex-matched controls. The different types of hyperlipidaemic 
subjects as described in the introduction will be assessed individually. 
As patients with hyperlipidaemia are more likely to have large vessel 
disease (which may be undetected clinically) an additional control 
group of patients with known peripheral vascular disease will be 
studied.
3. Platelet malondialdehyde production in washed platelets stimulated 
with arachidonic acid will be studied as a measure of the activity
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of the platelet prostaglandin pathway in subjects with diabetes and 
hyperlipidaemia and compared to control subjects.
4. The sensitivity of platelets from diabetic subjects to the anti­
aggregatory effects of prostacyclin will be studied in  v i t r o and 
compared to the responses seen in non-diabetic healthy controls.
5. The production of prostacyclin by tissues from 'acutely* and 
'chronically' experimental diabetic pregnant rats will be measured 
to determine #he time course of the known reduction in aortic 
prostacyclin production and to see whether prostacyclin production 
in another tissue, namely myometrium, is similarly affected.
6. Platelet aggregation will be studied in whole blood samples from 
diabetic subjects using the new impedenace aggregometer (Cardinal 
and Flower, 1980). This may be a more physiological approach to 
the study of platelet aggregation.
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METHODS
Measurement of Triglyceride and Cholesterol Concentrations
Total serum triglyceride and triglyceride concentrations of individual 
lipoprotein preparations were measured by a semi-automated fluorometric 
method (Cramp and Robertson, 1968) .
Total serum cholesterol and cholesterol concentrations of lipoprotein 
preparations were measured using Lieberman-Burchard reagent with a Locarte 
fluorimeter.
Isolation of Individual Lipoproteins
Individual fasting lipoprotein levels were measured by precipitation 
techniques.
VLDL was precipitated from 1 ml of serum in 17 x 58 mm glass tubes 
by the addition of 75 yl of 10% (W/V) SDS (BDH Chemicals 
Ltd.) in 0.15 mol/1 sodium chloride (Ononogbu and Lewis, 1976). After 
mixing, the tubes were incubated at 37°C in a water bath for 2 h. The 
tubes were then centrifuged (in an angle-head rotor) at 10,000 x g for 
20 min (in an MSE high speed 18 centrifuge). The clear infranatant was 
removed without disturbing the floating VLDL precipitate. The tube but 
not the VLDL pellet was washed with 0.1% SDS ( W/V) in
0.15 mol/1 sodium chloride. The VLDL pellet was then redissolved in 1 ml 
of 1% (W/V) SDS in 0.15 mol/1 sodium chloride at 37°C 
and an aliquot extracted in isopropanol for measurement of VLDL 
triglyceride and VLDL cholesterol. This method has been reported to 
give results which correlate well with VLDL measurements obtained by 
ultracentrifugation. For VLDL cholesterol, Ononogbu and Lewis (1976) 
found a correlation coefficient, r = 0.98 and for VLDL triglyceride, 
r = 0.99. In a series of 15 fasting serum samples obtained from patients 
studied for this thesis analysed by this method and by ultracentrifugation
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(Havel et aZ, 1955) correlation coefficients for VLDL triglyceride and 
VLDL cholesterol of r = 0.93 and r = 0.92 were obtained,
Chylomicra, VLDL and LDL were precipitated from serum by precipitation 
with polyanions (Burstein e t  àt^ 1970). Heparin (250 units in 50 yl)
(Weddel Pharmaceuticals) and manganese chloride (50 yl of 1 mol/1 solution) 
were added to serum (1 ml) in glass tubes on ice and the contents mixed 
on a vortex mixer. The tubes were left for 15 min on ice to allow complete 
precipitation of apoprotein B containing lipoproteins and then centrifuged 
at 2000 X  g for 20 min at 4°C. An aliquot of the resulting supernatant 
was then taken for measurement of HDL cholesterol and HDL triglyceride.
LDL cholesterol and LDL triglyceride values were obtained by subtracting 
the sum of HDL and VLDL values from the total serum cholesterol and 
triglyceride concentrations. In a series of 15 fasting serum samples 
obtained from patients studied for this thesis in which HDL concentrations 
were measured by heparin/manganese precipitation and by ultracentrifugation 
correlation coefficients were obtained for HDL cholesterol and HDL 
triglyceride of 0.93 and 0.91 respectively.
Platelet-Specific Proteins
Blood sampling for platelet-specific protein estimations were performed 
using a large-bore needle and without venous occlusion. Blood samples 
were immediately transferred to the sampling tubes (supplied with the assay 
kits) which had been pre-cooled on a mixture of ice and water. The 
sanples were mixed with the anticoagulant by gentle inversion of the tubes 
and replaced immediately in the ice/water mixture for 15 min. Samples 
were then centrifuged at 2000 x g at 4°C for 30 min to obtain platelet-poor 
plasma (PPP). Following centrifugation the top 0.5 ml PPP was carefully 
removed, and stored at -20°C prior to assay.
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6-Thromboglobulin and platelet factor 4 were measured by radioimmuno­
assay (3~thromboglobulin, $TG RIA kit. Amersham and platelet factor 4, PF4 
RIA kit, Abbott Laboratories, U.K.). These methods depend on competition 
between non-radioactive 3-thromboglobulin (or platelet factor 4) and 
labelled 3-thromboglobulin (or platelet factor 4) for a limited number of 
binding sites on specific antibodies to the platelet-specific protein. 
Thus, the amount of radioactive 3-thromboglobulin (or platelet factor 4) 
bound to antibody will be inversely proportional to the concentration of 
non-radioactive 3-thromboglobulin (or platelet factor 4) in the specimen. 
Antibody bound 3-thromboglobulin or platelet factor 4, both radioactive 
and non-radioactive, is separated by precipitation with ammonium sulphate 
solution, the radioactivity in this complex being measured using a gamma 
scintillation counter (Denley Automatic Gamma Counting System, Searle 
Analytic Inc.).
The concentration of 3-thromboglobulin (or platelet factor 4) in the 
plasma sample was determined by comparison with a group of standards 
containing known amounts of non-radioactive 3-thromboglobulin (or platelet 
factor 4). For both assays all estimations were performed in duplicate 
and the results were expressed as the means of the duplicate assays. For 
the 3-thromboglobulin assay the within assay coefficient of variation was 
6.9% and the between assay coefficient of variation was 10.4%. For the 
platelet factor 4 assay the within assay coefficient of variation was 7.7% 
and the between assay coefficient of variation was 6.3%. Samples from 
hyperlipoproteinaemic subjects were routinely measured undiluted and 
diluted 1:2 and 1:4 to detect any non-linearity of the assay due to high 
lipid concentrations.
Malondialdehyde Formation by Platelets
Platelet malondialdehyde formation used for the assessment of 
prostaglandin synthesis was performed in washed platelets stimulated by
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arachidonic acid (de Haas e t aZ, 1979). PRP was obtained following 
centrifugation of citrated (3.8%) venous blood at 170 x g for 15 min at 
room temperature. Platelet concentration in the PRP was determined with 
a Coulter Thrombo-Counter Model C. ADP (2 ymol)(Sigma) was added to the 
tubes containing PRP and- the tubes inverted several times to obtain 
flocculent aggregates (Mohamed e t dt^ 1975). The tubes were then 
centrifuged at 170 x g for 2 min to obtain a platelet pellet. The 
supernatant was discarded and the pellet resuspended in 10 ml of modified 
Tyrode’s buffer containing sodium chloride 137 mmol/1, potassium chloride 
2.68 mmol/1, calcium chloride 1.8 mmol/1, glucose 5.5 mmol/1, sodium 
dihydrogen orthophosphate (NaH2PO^2H20) 0.32 mmol/1 and magnesium chloride 
(MgCl26H20) 2 mmol/1.
Bovine serum albumin (0.35%) W/V)(Sigma) and potato apyrase (0.01% W/V) 
(Sigma) were added to this platelet suspension and the tubes incubated for 
15 min at 37°C. Following incubation the platelet suspension was 
centrifuged at 490 x g for 15 min at room temperature and resuspended in 
buffer aliquots of 10^ platelets/ml. Arachidonic acid (final concentration 
100 ymol/1) emulsified in physiological saline was added to the platelet 
suspension and the mixture incubated for 15 min at 37°C. The reaction was 
then stopped by the addition of 1 ml of thiobarbituric acid (36.7 mmol/1) in 
perchloric acid (229 mmol/1)(Stuart e t  d i , 1975). The tubes were then 
centrifuged at 2500 x g for 20 min at 4°C. The supernatant was decanted, 
boiled for 20 min and then allowed to cool at room temperature. The volume 
was then made up to 3 ml and the pink chromagen read at 532 nm using a 1 cm 
light path (Flower e t dly 1973). Results were expressed in nmol/10® 
platelets using an extinction coefficient of 1.37 x 10® for a molar solution
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Measurement of Glycosylated Haemoglobin
Glycosylated haemoglobin which is synthesized slowly over the life 
span of erythrocytes provides an objective means of assessing the average 
blood glucose concentration present in the weeks before sampling (Bunn e t  
dl^ 1976; Koenig e t  dl^ 1976). The percentage of glycosylated haemoglobin 
was estimated using a microscale ion-exchange column method (Welch and 
Boucher, 1978) for the study on platelet-specific proteins and malondi­
aldehyde formation. For the study on whole blood platelet aggregation 
in insulin-dependent diabetics, glycosylated haemoglobin was measured 
using agar gel electrophoresis (Corning).
Prostacyclin Production in Rat Tissue
Induction of Diabetes
Female Wistar rats (200-250 g) were made diabetic by injection of 
streptozotocin (80 mg/kg)(Sigma) into the tail vein. Streptozotocin 
2 deoxy-2-(3-methyl-3-nitrosoureido) D-glucopyranose, produces diabetes 
in rats following a single injection (Rakietin e t d l , 1963), Its 
diabetogenicity is related to pancreatic islet 3-cell cytotoxicity through 
the nitrosourea moiety. Control rats received an injection of vehicle 
only. The induction of diabetes was confirmed by blood glucose measurements 
using a glucose oxidase method; blood glucose concentration ranged from 
15-20 mmol/1 in the diabetic animals. One group of animals was made 
diabetic and mated after 5 weeks - the chronically diabetic group. A 
further group of animals was mated and diabetes was induced between days
7-17 of pregnancy (acutely diabetic). Animals were sacrificed on days 
20-22 of pregnancy (day 22 = day of delivery).
Tissue Isolation and Prostacyclin Estimation
Aortic and myométrial tissue sanç>les were prepared as described by 
Williams and El Tahir (1980a) and suspended (25% W/V) in gassed Kreb's
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solution, pH 8.0.
The reaction was initiated by chopping the sample finely with 
subsequent incubation for 15 min at 20°C. Aliquots of incubation media 
were then removed and stored on ice prior to assay.
The antiaggregatory activity in samples of incubation media was 
estimated against authentic prostacyclin (a gift of Wellcome Research) 
using rabbit citrated PRP, This technique is highly selective for 
prostacyclin. Estimates in myométrial incubation media show close 
correlation with ô-oxo-prostaglandin^^ levels determined by gas- 
chromatography/mass spectrometry and the intra- and inter-assay coefficients 
of variation were 5.6% and 6.9% respectively (Williams and El Tahir, 1980b).
Platelet Sensitivity to Prostacyclin
Venous blood was collected from overnight fasted control and diabetic 
subjects from an antecubital vein via a 19 gauge butterfly needle under 
gravity into 3.13% (W/V) sodium citrate (9 ml blood;1 ml citrate) contained 
in a plastic tube. The blood was centrifuged immediately at 200 x g for 
10 min at room temperature to obtain PRP. Aliquots of PRP (0.5 ml) were 
placed in a Bryston aggregometer and stirred at 1100 revolutions/min at 37°C, 
Platelet aggregation induced by the addition of ADP (Sigma) produced changes 
in the optical density of the PRP which were measured on a chart recorder.
In each experiment the minimal dose of ADP to produce irreversible 
aggregation for at least 3 min was determined. The ability of prostacyclin 
(a gift of Wellcome Research) to inhibit ADP-induced aggregation was 
investigated and a dose-response curve constructed. Prostacyclin was 
reconstituted in Tris buffer (0.Imoiyl^pH 9.6) and added 1 min prior to ADP. 
From these data the dose of prostacyclin causing a 50% inhibition of ADP- 
induced aggregation (ID^q) was calculated.
1.
Platelet Aggregation in Whole Blood
Venous blood was collected after an overnight fast from an antecubital 
vein via a 19 gauge butterfly needle under gravity into 3.13% (W/V) 
trisodium citrate, pH 7.4 (18 ml blood:2 ml citrate) in a plastic tube. 
Platelet aggregation was measured with a Chronolog Model 540 whole blood 
aggregometer (Coulter Electronics Ltd.) connected to a Rikadenki pen 
recorder. The aggregometer stirring speed was set at 600 rpm and 
temperature at 37°C. When the calibration button was depressed (giving 
a fixed impedence of 5 ohm) , the gain control was adjusted such that a 
deflection of 25 mm was obtained. The recorder was set at 100 MV full 
scale deflection with a rate of 2 cm/min. Platelet aggregation was 
studied in response to two concentrations of collagen (1 yg/ml and 5 yg/ml) 
(Immuno Ltd.) and 1 mmol/1 arachidonic acid (Sigma)(final conentrations).
In addition the sensitivity of platelets to the antiaggregatory action of 
prostacyclin was assessed. Blood samples (adjusted to standardized haematocrit 
(0.300) with saline) (975 yl) were warmed for 3 min at 37°C in the machine
heater block and then stirred with a teflon coated stir bar in a glass
cuvette after inserting the impedance electrode. A period of 2 to 3 min 
was necessary for the platelet monolayer to form and the base line to 
become steady. The aggregating agent (25 yl) was then added and aggregation 
allowed to continue until a maximum was reached (up to 8 min). Both rate
(SZ/min) and the extent of aggregation (f̂ ) were measured.
For the prostacyclin sensitivity studies, prostacyclin was added 
1 min before the addition of arachidonic acid (final concentration 1 mmol/1). 
Prostacyclin was reconstituted in Tris buffer (0.1 mmol/1, pH 9.6)and lOyl 
added to the whole blood sample (965 yl), final pH 7.4. Increasing 
concentrations of prostacyclin (0.5 - 20 ng/ml) were added and the mid­
point between a concentration that did not inhibit and a concentration 
that inhibited totally is described here as the prostacyclin ID^^.
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RESULTS
Studies in Diabetic Patients 
Platelet-Specific Proteins
One hundred and forty-three diabetic subjects, 90 non-insulin 
dependent and 53 insulin dependent, were studied. All patients received 
a careful clinical examination with particular reference to the presence 
or absence of diabetic complications. Patients were examined for the 
presence of fundal microaneurysms, haemorrhages and exudates and new 
vessel formation following dilatation of the pupils. Forty-two patients 
had clinical evidence of retinopathy, twenty with new vessel formation.
No patient had had recent laser therapy for retinopathy. The presence 
of large vessel disease was determined by the following criteria : 
previous myocardial infarction was recorded when electrocardiographic and 
cardiac enzyme evidence supported an appropriate clinical history. A 
positive history of angina pectoris was recorded when the patient experienced 
recurring attacks of typical exertional anterior chest pain, usually with 
radiation that was relieved by rest or nitroglycerin. A documented history 
or evidence of a previous cerebrovascular accident was recorded. Pain in 
the leg muscles when walking, especially in the calves, that disappeared 
with rest, was considered to be intermittent claudication. Loss of limb 
pulses was recorded. Twenty patients had clinical evidence of large 
vessel disease. None of the patients had evidence of renal impairment.
The diabetic patients were compared to groups of apparently healthy 
age- and sex-matched controls with no history and no clinical evidence of 
vascular disease drawn from laboratory and hospital staff. Both diabetics 
and controls had not taken platelet-suppressive drugs for at least two 
weeks prior to blood sançling. Diabetic patients had not suffered a 
hypoglycaemic reaction for at least four weeks prior to the study.
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Plasma g-Chromboglobulin was measured in all the one hundred and 
forty-three diabetic subjects and the results are shown in Figure 3.
It can be seen that there is considerable overlap for 3-thromboglobulin 
levels between diabetic and control subjects. However 27.3% of diabetics 
had 3-thromboglobulin levels greater than the highest level seen in the 
control group. The mean and range of 3-thromboglobulin levels for controls 
and diabetics are shown in Table 5.
Levels of platelet factor 4 found in diabetic and control subjects are 
shown in Figure 4 and Table 5. Platelet factor 4 was measured in 26 
insulin dependent and 54 insulin independent diabetics (36 males and 44 
females). 31.3% of diabetics had levels of platelet factor 4 greater 
than the highest level observed in age- and sex-matched controls.
Statistical analysis for both the 3-thromboglobulin and platelet 
factor 4 results showed these differences to be highly significant (Table5).
No differences were found for 3-thromboglobulin and platelet factor 4 
levels between male and female diabetics or between insulin dependent and 
non-insulin dependent patients. There were strong correlations (Spearman 
test) between 3-thromboglobulin and platelet factor 4 levels both in control 
subjects (R = 0.5012; P < 0.001) and diabetics (R = 0.7631; P < 0.001).
The platelet specific protein data in the diabetics were analysed in 
relation to the presence or absence of diabetic complications (Table 6 ). 
Those diabetics with clinical evidence of retinopathy had slightly higher 
levels of 3-thromboglobulin and platelet factor 4 than those diabetics 
without retinopathy and these differences reached statistical significance 
for 3-thromboglobulin (Table 6 ). Mean 3-thromboglobulin (74.4 ng/ml) 
and platelet factor 4 (48.45 ng/ml) levels in diabetics with large vessel 
disease were not significantly higher than diabetics without vascular 
disease. However these diabetics together with those patients with no 
apparent vascular disease differed significantly from controls.
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B“Thromboglobulin levels (ng/ml) in ]43 diabetics and 
143 age- and sex-matched controls. Points are means 
of duplicate assays.
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Figure 4
Platelet factor 4 levels (ng/ml) in eighty diabetics 
and eighty age- and sex-matched controls. Points are 











3-Thromboglobulin 36.3 143 53.5 72.6* 143 56.8
(ng/ml) (8-95) (21-80) (14.0-220) (20-81)
Platelet factor 4 16.5 80 55.9 48.5* 80 57.8
(ng/ml) (6.6-29.6) (21-80) (9.0-193) (20-79)
Malondialdehyde
formation
8.1 30 29.7 12.4* 48 53.7
(nmol/10® platelets) (5.4-13.0) (14-50) (5.1-26.8) (20-79)
* P<0 .0005.
Table 5. Levels of plasma 3-thromboglobulin, of platelet factor 4 and 
malondialdehyde formation in diabetic and control subjects. 
Statistical analysis by chi-squared test.
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Diabetic patients
With retinopathy No. Without retinopathy No. Significance
3“Thromboglobulin 79.0 42 70.0 101 P<0.042
(ng/ml) (18-167) (14-220)
Platelet factor 4 55.9 32 44.3 48 NS
(9.3-191.5) (9.0-193)
Table 6. Levels of plasma 3-thromboglobulin and platelet factor 4 in
diabetics with and without retinopathy. Statistical analysis 
by chi-squared test.
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Table 7, Correlation between plasma 3“thromboglobulin levels (3TG) 
and individual serum lipid and lipoprotein concentrations 
(Spearman correlation).
3TG V, Total triglyceride
3TG V, VLDL triglyceride
3TG V, Total cholesterol
3TG V. LDL cholesterol








In order to determine whether the elevated levels of platelet specific 
proteins observed in the diabetic group studied were related to diabetic 
control correlations were sought with glycosylated haemoglobin concentrations 
Glycosylated haemoglobin levels were measured in 62 diabetic subjects (mean 
glycosylated haemoglobin 12.4%, range 8-19.6%). No correlation was found 
between levels of platelet specific proteins and the concentrations of 
glycosylated haemoglobin.
As important interactions have been described between lipoproteins and 
platelets and diabetes is an important cause of secondary lipid and 
lipoprotein abnormalities (see Introduction) correlations were sought with 
plasma levels of 3~thromboglobulin and fasting plasma lipid and lipoprotein 
concentrations. These measurements were performed on 49 of the diabetic 
patients. Small but statistically significant correlations (Spearman 
test) were found between 3-thromboglobulin levels and fasting plasma 
concentrations of individual lipids and lipoproteins as shown in Table 7.
Malondialdehyde Formation
Platelet malondialdehyde formation was measured zn vz tro in washed 
platelets stimulated by arachidonic acid in 23 insulin dependent and 
23 non-insulin dependent subjects and compared to 30 control subjects 
(Table 5 and Figure 5 ) . No difference in malondialdehyde formation 
was seen between platelets from non-insulin dependent and insulin dependent 
diabetic subjects.
34.1% of diabetics had levels of malondialdehyde formation greater 
than the highest result seen in the control group and this difference was 
highly significant (Table 5). Levels of malondialdehyde formation zn 
v ztro in diabetic subjects were significantly correlated (Spearman test) 
with plasma levels of 3-thromboglobulin (R = 0.4736; P < 0.002, n=46) and 
with plasma levels of platelet factor 4 (R = 0.6006; P < 0.009; n=21).
90
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C n = AS )
Figure 5
Malondialdehyde formation (nmol/10* platelets) 
in forty-six diabetics compared to thirty 
controls. Points are means of duplicate 
measurements.
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Platelet Sensitivity to Prostacyclin
Sensitivity to the anti-aggregatory effects of prostacyclin was studied 
in a group of diabetic patients and control subjects. The clinical details 
of the diabetic patients studied are shown in Table 8\. The presence or 
absence of complications in the diabetic patients was determined as 
previously described. The patients had had no recent hypoglycaemic attacks 
and mean preprandial blood glucose estimations ranged from 6.5 to 11.8 mmol/1 
Control subjects were normal healthy volunteers from medical and laboratory 
staff. Neither diabetic patients nor control subjects had taken medication 
known to affect platelet function for at least two weeks prior to study.
An aggregation tracing using PRP from a control subject is shown in 
Figure 6a. Addition of ADP (final concentration 1 ymol/1) produced 
irreversible aggregation. Addition of prostacyclin to the PRP 1 min prior 
to the addition of ADP produced a dose-dependent inhibition of platelet 
aggregation. Figure 6b shows a similar aggregation tracing using PRP from 
a diabetic subject. Irreversible aggregation was produced by a similar 
concentration of ADP to that used in the control plasma. However, there 
was a marked difference in the concentration of prostacyclin required to 
inhibit ADP-induced aggregation. 1.25 ng prostacyclin added to the cuvette 
(final concentration 2.5 ng/ml) exerted minimal anti-aggregatory activity 
and addition of 5 ng (final concentration 10 ng/ml) was required to cause 
a 32% inhibition of the ADP-induced aggregation. This is 8 times the 
amount of prostacyclin needed to cause a similar inhibition to that in 
the control PRP.
Cumulative data from control and diabetic subjects obtained by the 
same experimental procedures are shown in Figure 7 and Table 8 As 
can be seen there is considerable overlap in prostacyclin ID^^ values 
between diabetics and controls; however 30% of diabetics had ID^^ values 
greater than the highest control value obtained. This difference was
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Platelet aggregation tracings showing the inhibitory effect of the prior 
addition of increasing amounts of prostacyclin on platelet aggregation 






(n g /m l)
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Calculated prostacyclin ID50 values (ng/ml) 
for platelets from control subjects and diabetic 
patients. P<0.01 (Wilcoxon Rank Sum test).
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statistically significant using the Wilcoxon Rank Sum test, P < 0.01.
No difference was found in the sensitivity of platelets to prostacyclin 
between insulin dependent and non-insulin dependent patients (see Table 8 ) 
and there was no correlation with, age in the control or diabetic group 
and no correlation with the duration of disease in the diabetics. Those 
diabetics with clinical evidence of large vessel disease had prostacyclin 
ID^q values much greater than those diabetics without vascular disease 
(P < 0.01). Diabetics without large vessel disease had higher values
than controls but this difference did not reach statistical significance 
(see Table 8 ) .
Prostacyclin values did not differ significantly between diabetics
with retinopathy (n=9) and diabetics without retinopathy or control subjects.
Whole Blood Platelet Aggregation
Twenty insulin dependent diabetic subjects (12 females and 8 males, 
mean age 37.3 years, range 18-63 years) and 20 age- and sex-matched 
controls (mean age 38.6 years, range 24-58 years) were studied. The mean 
duration of diabetes was 12.8 years. Control subjects were normal healthy 
volunteers drawn from hospital and laboratory staff. No patients or 
control subjects had taken drugs affecting platelet function for at least 
twenty-one days and the diabetics had no recent history of hypoglycaemia.
The diabetics chosen for this study had no clinical evidence of complications 
Optic fundi were carefully examined following dilatation of the pupil to 
exclude retinopathy. The patients had normal renal function with no 
proteinuria and there was no clinical evidence of neuropathy. Clinical 
macrovascular disease was excluded as far as possible by a careful history 
and examination. Resting electrocardiograms were normal in all patients.
The results of whole blood platelet aggregation in response to collagen 
(1 pg/ml) and arachidonic acid(Immol/Î for the diabetic and control groups 
are shown in Figure 8 and Figure 9 respectively.
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Whole Blood Platelet Aggregation 











F ig u re  8
The rate (Q/roin) and the extent (S7) of whole blood platelet aggregation 
induced by collagen (final concentration lv>g/ml) in diabetics and controls 
(n=20). Statistical analysis (Wilcoxon).













Controls (p q5) Diabetics
Figure 9
The rate (Q/min) and the extent {Ü) of vhole blood platelet aggregation 
induced by arachidonic acid (final concentration imraol/l) in diabetics and 















(p  <  .05)
Figure 10
Calculated prostacyclin ID30 results (ng/ml) for diabetics and 















































































Correlation of prostacyclin results (ng/ml) for diabetics and
the levels of glycosylated haemoglobin percentage.
(n = 11) (p < 0.05 Kendal).
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It can be seen that both the rate and extent of aggregation to the 
collagen was significantly increased in the diabetic group compared to 
controls. A significant increase in the extent but not the rate of 
aggregation was seen for arachidonic acid. No significant difference 
was found between diabetics and controls in aggregation studies performed 
with collagen in higher dose, 5 yg/ml (data not shown).
The sensitivity of platelets in whole blood to the anti-aggregatory 
effects of prostacyclin is shown in Figure 10. A sample experimental 
tracing is shown in Figure 11. Diabetics showed a significantly reduced 
sensitivity to prostacyclin.  ̂ In addition there was a significant positive 
correlation between glycosylated haemoglobin and the prostacyclin ID^^ 
(Figure 12).
Prostacyclin Production by Tissues from Pregnant Diabetic Rats
The prostacyclin-like activity synthesised by tissues from acutely 
diabetic animals killed on day twenty-two of pregnancy is shown in 
Figure 13. Aortic tissue from control rats produced 5.75 ±1.23 ng 
prostacyclin/mg (mean ± SEM, n=8) and this was reduced to 3.45 ± 1.12 ng/mg 
in diabetic animals but this reduction was not statistically significant. 
Similarly there was no significant depression of myométrial prostacyclin 
production; control sanples released 4.52 ±0.3 ng/mg compared with 
3.9 ± 0.31 ng/mg from the diabetic samples.
In chronically diabetic rats a marked reduction in aortic prostacyclin 
synthesis was noted; an aggregation tracing from one experiment is shown 
in Figure 14). The tracing shows the aggregation response induced in 
rabbit PRP by ADP (10 pmol/1 final concentration). Equivalent
volumes of myométrial incubation media from control and diabetic animals 
contained similar quantities of anti-aggregatory material. However an 
aliquot of aortic incubation medium from a control animal was found to 
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.Figure 13
Effect of acute experimental diabetes on prostacyclin (PGI2) production 
by aortic and myométrial tissues from pregnant rats. PGI2 release 
from control (batched bars) and diabetic tissues (open bars) are 
shown. Columns show mean ± SEM.
8 experiments. NS (Student's t-test).
0 3 .
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Figure 14
Aggregation tracing showing anti-aggregatory material released by aorta 
and myometrium from chronically diabetic rats. Aggregation was induced 
by ADP (10 pM) • Authentic prostacyclin produced dose-related inhibitions 
of the ADP-induced response. Aliquots of myométrial incubation media from 
diabetic and control animals contained similar amounts of prostacyclin. 
However medium from the diabetic aortic sample contained markedly less 
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Figure 15
Effect of chronic experimental diabetes on prostacyclin (PGI2) 
production by aortic and myométrial tissues from pregnant 
rats. release from control (hatched bars)
and diabetic (open bars) tissues are shown. Columns 
shown mean ± SEM.
9 experiments. *P<0.001. (Student's t-test).
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after incubation of aorta from a chronically diabetic animal contained 1 ng. 
This represents a 60% decrease in prostacyclin release.
The cumulative findings from a series of experiments utilizing 
chronically diabetic animals are shown in Figure 15. In aortic tissue 
control prostacyclin synthesis was 2.5 ± 0.39 ng/mg compared with 
0.85 ± 0.12 ng/mg in tissue from chronically diabetic rats, this reduction 
is significant (P < 0.001). However prostacyclin output by myométrial 
tissue from control and diabetic animals did not differ.
Studies in Hyperlipidaemic Patients 
Platelet Specific proteins
Sixty-nine patients with hyperlipidaemia were studied and compared to 
age- and sex-matched healthy controls drawn from hospital and laboratory 
staff (Table 9 ). The hyperlipidaemic subjects were classified according 
to the World Health Organisation classification (Beaumont e t 1970).
None of the patients had diabetes mellitus, thyroid disease, hepatic or 
renal disease. None of the hyperlipidaemic women was taking the 
contraceptive pill. In addition to the hyperlipidaemic and control groups, 
57 patients (mean age 63.5 ± 2.11 SEM) with peripheral vascular disease and 
no diabetes or hyperlipidaemia (cholesterol < 7 mmol/1; triglyceride 
< 2.0 mmol/1) were studied by measurement of 3~thromboglobulin values in 
PPP. The.patients, with peripheral vascular disease were 
clinically well documented by the Department of Vascular Surgery, King's 
College Hospital.
The mean plasma 3~thromboglobulin was higher in the hyperlipidaemic 
patients than in the healthy controls (Figure 16). There was some overlap 
between the 3“thromboglobulin values of patients and controls but in 46 
patients (21 with type Ila, nine with lib and sixteen with type IV), or 
67% , the values were beyond the highest value for the control group.
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Age (yr)*
Hyperlipidemia No. and Sex Patients Controls.
Ila 18, M 50.3 + 2.54 48.8 + 4.58
14, F 53.4 + 2.88 52.1 + 3.62
Ilb 13, M 53.7 + 3.04 54.8 + 4.6
2, F 46.5 47
IV 18, M 50.5 + 2.04 49.2 + 4.2
4, F 57.5 + 1.66 56.5 + 2.4
Total 49, M 51 .3 + 1.43 50.5 + 2.79
20, F 53.5 + 2.43 52.5 + 2.84
Values given are the mean ± 1 standard error of the mean.
Table 9 Clinical details of hyperlipidémie patients classified 
according to the WHO classification and age- and sex- 
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Figure 16
Mean (horizontal lines) and range of plasma 3-thromhoglohulin 
(ng/ml) in 69 patients with three types of hyperlipidaemia, 
and age- and sex-matched controls. The difference (Student 
unpaired t-test) between the mean logarithmic values in 
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Mean (horizontal lines) and range of plasma platelet 
factor 4 (ngl/ml) in 48 patients with three types of 
hyperlipidaemia and age- and sex-matched controls.
The difference (Student unpaired t-test) between the 
mean logarithmic values of patients and controls was 
highly significant (P<0.001 in patients with type Ila 
and type IV hyperlipidaemia and P<0.002 in those with 
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Figure 18
Linear regression analysis correlating plasma 3“thromboglobulin 
values to platelet factor 4 in 48 hyperlipidaemic patients. 
(r=0.69B6, P<0.001 and 95 percent confidence limits:
0.516 <r <0.768).
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Statistically the difference between the mean logarithmic level of 
3-thromboglobulin of patients and controls was highly significant (Table 10 ). 
The mean logarithmic 3~thromboglobulin level was higher in patients with 
type lib and type IV hyperlipidaemia than in those with type Ila hyper­
lipidaemia but this difference was not significant (Students unpaired 
t-test).
The mean plasma 3“thromboglobulin level was also higher in the 
hyperlipidaemic patients than in the patients with peripheral 
vascular disease (mean 62.5 ng/ml, range 16-160 ng/ml but with much overlap. 
Statistically the difference between the mean logarithmic 3“thromboglobulin 
value in these patients was highly significant (P < 0.009 for type Ila 
hyperlipidaemia, P < 0.017 for type lib hyperlipidaemia and P < 0.001 
for type IV hyperlipidaemia (Students unpaired t-test) . However the mean 
logarithmic 3~thromboglobulin level was significantly elevated in the 57 
patients with peripheral vascular disease compared to that in age- and 
sex-matched controls (P < 0.001).
The mean plasma platelet factor 4 level was higher in 48 hyperlipidaemic 
patients studied conq)ared to healthy controls (Figure 17, Table 10). Again 
considerable overlap was observed but 31 patients (16 out of 22 with type Ila 
hyperlipidaemia, 7 out of 10 with type lib hyperlipidaemia and 8 out of 12 
with type IV hyperlipidaemia), or 65%, the plasma platelet factor 4 
level was beyond the upper range for controls. Statistically the 
difference between the mean logarithmic platelet factor 4 value of the 
patients and controls was highly significant (Table 10). There was no 
significant difference among the mean logarithmic platelet factor 4 values 
for the three groups of hyperlipidaemic patients.
Using linear regression analysis a strong positive correlation between 
3“thromboglobulin and platelet factor 4 was found in the hyperlipidaemic 
subjects (P < 0.00])(Figure 18). Similar correlations were obtained when 
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Ma1ondialdehyde Formation
The mean platelet malondialdehyde formation was higher in the patients 
than in the healthy controls (Figure 19 , Table 11). The overlap between 
patients with type Ila hyperlipidaemia and controls was almost total; 
however, in 5 of 9 patients with type lib hyperlipidaemia and 7 of 16 
patients with type IV hyperlipidaemia, malondialdehyde formation was 
beyond the upper range for controls (Figure 19). Statistically the 
difference between the mean logarithmic malondialdehyde value of the 
three groups of patients and the controls was significant Table 11).
In addition there was a significant difference (P < 0.016) between the 
mean logarithmic malondialdehyde value of those with type lib and type IV 
hyperlipidaemia compared to those with type Ila hyperlipidaemia.
There was a strong positive correlation between 16 logarithm values 
of plasma 3-thromboglobulin and platelet malondialdehyde formation in 
type IV hyperlipidaemia (r = 0.7660, P < 0.003).
Clinically 25 out of the 69 hyperlipidaemic patients suffered from 
large vessel disease (ischaemic heart disease, peripheral vascular 
disease or chronic cerebrovascular disease). In these patients 
malondialdehyde formation together with 3~thromboglobulin and platelet 
factor 4 values were slightly higher than in the remaining patients with 
no apparent vascular disease. However the difference between the two 








Controls _  
n = 3 0  Type i j  a 
n r  26
Type j j  b 
n =  9 T y p e l y  
n=16
Figure J9
Mean (horizontal lines) and range of malondialdehyde 
formation (nmol/lO* platelets) by washed platelets 
of 51 patients with three types of hyperlipidaemia 
and 30 controls. The difference (Student unpaired 
t-test) between the mean values of patients and 
controls was highly significant, (P<0.001 in patients 
with type lib and type IV hyperlipidaemia, and P<0.01A 
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Studies in Diabetic Patients 
Platelet-Specific Proteins
In recent years it has become possible to measure the platelet 
specific proteins 3~thromboglobulin and platelet factor 4 (Moore e~t 
at,. 1975; Niewiarowski e t  a t 1969) . These proteins are stored within 
the platelet alpha-granules (Niewiarowski, 1977) and are released to 
the surrounding plasma during platelet aggregation induced by thrombin 
collagen, ADP, adrenaline and various lectins (Ho1msen e t  a t 1969;
Ho1msen, 1975). $-Thromboglobulin is the most abundant platelet- 
specific protein with a platelet concentration 30-10** times higher 
than in other tissues (Ludlam, 1979). Since 6-thromboglobulin is 
cleared from human plasma with a half“life of 100 min at 37°C (Dawes 
e t a t 1978) an elevated level in platelet-poor plasma may be a useful 
indicator of enhanced "LM vtvo platelet activation and 'release reaction*. 
In fact plasma 3"thromboglobulin levels were shown to correlate closely 
to platelet lifespan (Ludlam, 1979). Platelet factor 4 on the other hand 
because of its very short half-life (Musial e t a t 1980) is less sensitive 
than 3~thromboglobulin in detecting platelet secretion tn  vi/00 but it is 
a useful marker of artifactual secretion in  v itv o (Kaplan and Owen, 1981)
In the results reported in this thesis 3~thromboglobulin levels in 
platelet-poor plasma were found to be highly significantly elevated in 
diabetic subjects compared to age and sex matched non-diabetic control 
subjects. Similar findings were observed for platelet factor 4 levels 
and the close correlation observed between 3~thromboglobulin and platelet 
factor 4 levels both in diabetic subjects and control subjects suggested 
that the elevated 3“thromboglobulin levels were not due to in  v itv o  
release reaction. Indeed great care was taken in these studies to follow
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as carefully as possible the measures described by Zahavi e t  a t (1980) 
to achieve accurate determination of 3-thromboglobulin and platelet 
factor 4. Clean venepuncture was performed without venous stasis and 
the blood was collected into cooled anticoagulant containing tubes, 
separated immediately by centrifugation (2000 x g) at 4°C for 30 min to 
obtain platelet-poor plasma which was immediately frozen at -20°C to wait 
analysis.
Previous studies of 3-thromboglobulin levels in diabetic subjects 
have yielded conflicting results. Whereas in one study no significant 
increase in 3~thromboglobulin levels was found (Campbell e t  àt^ 1977) 
other studies revealed higher levels of 3~thromboglobulin in diabetic 
patients (Burrows e t  a l , 1978; Preston e t al^ 1978). Campbell e t a t (1977) 
had suggested that the reason for the discrepant findings of these studies 
was that in their study prostaglandin E^ was added to the anticoagulant 
mixture whereas in the other studies this was not present in the anti­
coagulant mixture. However Horsey e t  a t (1980) measured 3~thromboglobulin 
using four different techniques and although levels of 3“thromboglobulin 
were lower when prostaglandin was present in the anticoagulant they 
remained elevated in diabetic subjects. In addition it is unlikely that 
this factor would be independent of the type of subject studied and would 
occur both in the diabetics studied as well as the healthy controls.
In the early studies of 3~thromboglobulin levels in diabetic subjects 
the number of patients studied was small and they were not compared to 
age- and sex-matched control subjects. This is of importance as in some 
studies of 3-thromboglobulin in non-diabetic populations a significant 
increase in levels has been seen with increasing age (Ludlam, 1979;
Zahavi e t at^ 1980), although Dewar e t  a t (1979) did not demonstrate this 
relationship. Also in one study there was a sex difference in old healthy
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subjects (Zahavi e t  aly 1980). In this thesis the study of the platelet- 
specific proteins 3“thromboglobulin and platelet factor 4 has been extended 
to a large group of diabetic patients compared to a group of non-diabetic 
healthy individuals well-matched for age and sex. The findings of 
elevated levels of 3-thromboglobulin and platelet factor 4 in diabetic 
subjects provide further evidence that in  vivo platelet activation and 
release reaction is enhanced in diabetes.
3-Thromboglobulin levels have been shown to be elevated in various 
types of vascular disease. Ludlam e t  a l (1975) found elevated levels 
in patients presenting with subacute venous thrombosis. Stewart e t  a l  
(1983) described significantly higher levels of platelet-specific proteins 
in patients with transient cerebral ischaemia and Handin e t  a l (1979) found 
elevated levels in patients following myocardial infarction. Celia e t  a l  
(1979) found elevated 3“thromboglobulin levels in patients with peripheral 
vascular disease but not in patients with cerebrovascular disease. Because 
of these findings the diabetic subjects studied in this thesis were 
carefully examined to discover which of them had evidence of vascular 
complications. This was done to try and separate within the diabetic 
subjects studied effects on 3-thromboglobulin due to pre-existing 
vascular disease and effects due to the altered metabolic state. 
Unfortunately present clinical methods cannot rule out early vascular 
disease, particularly large vessel disease, and until non-invasive 
imaging techniques are available, possibly involving nuclear magnetic 
resonance, complete exclusion of vascular disease will not be possible.
The results for the platelet-specific proteins were analysed therefore 
within the diabetic subjects depending on the presence or absence of
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complications. An interesting and important finding to emerge following 
this analysis was that those diabetics without clinical evidence of 
vascular disease still had highly significantly elevated 3~thromboglobulin 
levels when compared to age and sex-matched controls. Those diabetics 
with clinical evidence of retinopathy had small but statistically 
significant elevations of 3~thromboglobulin compared to diabetics without 
retinopathy. No difference was seen for 3-thromboglobulin levels for 
diabetics with and without clinical large vessel disease. These 
findings suggest that abnormalities in in  vivo platelet activation and 
release reaction may precede the development of vascular complications 
in the diabetic and imply that the abnormalities are related in some way 
to the abnormal metabolic state. This is in keeping with the findings 
of Preston e t  a l (1978) who found elevated levels of 3~thromboglobulin 
in a small group of newly diagnosed diabetic subjects. However there 
are other factors apart from hyperglycaemia in the altered metabolic 
state of diabetes which might directly affect platelet function or 
indirectly affect platelets by actions on vascular endothelium. In the 
present study glycosylated haemoglobin which gives an overall assessment 
of glycaemic control over a 4-6 week period (Bunn e t  à t 1976) was measured 
as an assessment of glucose homeostasis in 62 of the diabetics studied.
In these diabetics no correlation was found between glycosylated haemo­
globin and levels of platelet specific proteins. In an early study of 
3-thromboglobuIin in a mixed group of 72 diabetic subjects no correlation 
was found with simultaneous measurements of plasma glucose concentrations 
(Burrows e t  a l 1978). Platelet factor 4 showed a significant positive 
correlation with plasma glucose concentration in a small group of insulin- 
dependent diabetics but no correlation was seen for 3-thromboglobulin 
and no relationship was found for either of the platelet specific proteins 
in a larger group of non-insulin dependent diabetics (Davi e t  a l 1982).
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The findings in this thesis of no correlation between platelet-specific 
protein levels and glycosylated haemoglobin concentrations are in 
agreement with findings from other studies (Davi e t  a t , 1982; Mathews 
e t d l, 1979).
Equally conflicting results with regard to glycaemic control and 
platelet-specific protein levels have been reported in longitudinal 
studies. In 9 newly diagnosed non-insulin-dependent diabetics mean 
3-thromboglobulin levels fell from 74 ng/ml (range 24-277 ng/ml) to 
39 ng/ml as treatment with diet and hypoglycaemin agents reduced mean blood 
glucose concentrations from 14.3 to 8.5 mmol/1 (Preston e t  dl^ 1978).
However in longitudinal studies of moderately well controlled insulin- 
dependent diabetics treated with constant subcutaneous insulin for 2 
weeks (Delamothe and Betteridge, 1985) or 4-8 weeks (Rosove e t  dl^ 1984) 
which led to significant lowering of mean plasma glucose and glycosylated 
haemoglobin levels, no changes were observed in platelet factor 4 or 
3-thromboglobulin levels. On the other hand in a short term study using 
the artificial pancreas, normalisation of blood glucose for 48 h led 
to a significant fall in 3-thromboglobulin (Voisin e t  dty 1983).
As has been seen in the introduction to this thesis hyperlipoproteinaemia 
is common in diabetes mellitus. Therefore in this thesis correlations 
were sought between platelet-specific protein levels and fasting total 
serum cholesterol and serum triglyceride and the individual lipoproteins. 
These measurements were available in 49 of the diabetic subjects studied. 
Small but statistically significant correlations were found between 
3-thromboglobulin levels and total triglyceride, VLDL-triglyceride, 
LDL-cholesterol and HDL/total cholesterol ratio. The correlations 
were positive apart from the correlation with HDL/total cholesterol which 
was negative. These findings suggest that changes seen in platelet
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specific proteins in diabetes might be secondary to associated hyper­
lipoproteinaemia. In addition these correlations between individual 
lipid and lipoprotein concentrations and platelet-specific proteins 
may explain the changes of platelet specific proteins with instigation 
of diabetic therapy (Preston e t d l 1978), as lipid levels would be 
expected to be elevated in uncontrolled diabetes and to fall with improved 
control (Simpson e t a t 1979; Paisey e t  a t 1978). As will be discussed 
later in this thesis the lipid environment of the platelet may directly 
affect platelet function. In addition recent experimental work has 
suggested that lipoproteins (VLDL) obtained from diabetic animals 
(streptozotocin diabetic rats) may be more toxic to cultured porcine 
endothelial cells than lipoproteins obtained from control animals. This 
effect which may be due to increased lipid peroxide levels in diabetes 
was reversed by insulin treatment (Arbogast e t a t 1982). Other studies 
have shown increased lipid peroxide levels in lipoproteins isolated from 
diabetic patients (Nishigaki e t  a t 1981) and animals (Higuchi, 1982).
These findings suggest that lipoprotein abnormalities in the diabetic 
state may also indirectly affect platelet function by damaging vascular 
endothelium. There is as yet no direct measure of endothelial damage 
in the intact animal. However, some recent studies have measured 
plasma levels of Factor Vlll-related antigen as an indirect measure of 
endothelial cell damage together with 3“thromboglobnlin levels. Rak e t  
a t (1983) found that plasma levels of both proteins were elevated in 
diabetics including children. It is difficult to determine therefore 
whether endothelial damage preceded the evidence of enhanced platelet 
release reaction or not. Janka e t a t (1983) studied Factor Vlll-related 
antigen and g-thromboglobulin levels in groups of diabetics with and 
without vascular disease. These authors found an increase in Factor 
Vlll-related antigen in all groups of diabetics whereas 3-thromboglobulin
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was only elevated in diabetics with retinopathy. This study suggests 
that endothelial damage (as assessed by Factor Vlll-related antigen 
levels) may precede evidence of in vivo platelet aggregation but obviously 
further work needs to be done in this area.
So far this discussion has dealt with the elevated levels of platelet 
specific proteins purely as a likely measure of enhanced in vivo platelet 
release reaction in diabetic subjects. However, do these platelet 
specific proteins have a physiological role in their own right? The 
important platelet mitogen, platelet-derived growth factor which is an 
alpha granule constituent along with 3-thromboglobulin and platelet factor 
4 has been discussed in the introduction to this thesis. Both 
3“thromboglobulin and platelet factor 4 have anti-heparin activity.
However it is doubtful whether this property of the platelet specific 
proteins has any physiological importance since the concentration of 
heparin is probably insignificant (Niewiarowski and Paul, 1981). Never­
theless these proteins also react with other glycos aminoglycans such as 
heparin sulphate (Barber e t d l 1972; Niewiarowski e t  d l 1979). Heparin 
sulphate occurs on the surface of many cells including endothelial cells 
(Lindahl and Hook, 1978) and there is evidence that both platelet factor 4 
(Busch e t d l 1980) and 3-thromboglobulin (Hope e t d l 1979) bind to 
cultured endothelial cells. In addition 3-thromboglobulin appears to 
inhibit prostacyclin synthesis in bovine aortic endothelial cells (Hope 
e t a l 1979). Platelet factor 4 appears to act as an inhibitor of 
collagenase which suggests a possible physiological role in connective 
tissue metabolism (Hiti-Harper e t a t 1978). However the possible 




As discussed in the introduction to this thesis prostaglandins, 
thromboxanes and their precursor arachidonic acid are critical substances 
in platelet metabolism (Samuelson’, 1977). Earlier studies of the prosta­
glandin pathway in platelets from diabetic subjects measured the classical 
prostaglandins. Thus Halushka e t  a l  (1977) demonstrated that diabetic 
platelets synthesized greater amounts of prostaglandin E^ in response 
to various agonists compared to platelets from matched control subjects.
Most of the patients studied were free of vascular disease. Subsequently 
increased serum concentrations of the prostaglandins E^ and F^^ were 
demonstrated in the serum of diabetic children (Chase e t  aly 1979).
Although these findings indicate increased activity of the platelet 
prostaglandin pathway in diabetic subjects they do not explain the 
increased platelet aggregation as these prostaglandins are not in themselves 
aggregatory.
The formation of the potent aggregating substance thromboxane A^ in 
diabetic platelets has to be assessed indirectly because it is very labile 
with a half-life of approximately 30 sec in aqueous solution (Hamberg e t  aly 
1975). In this thesis malondialdehyde formation was used as an indirect 
measure of thromboxane A^ production in platelets stimulated by arachidonic 
acid. Malodialdehyde is a stable product of the conversion of endoperoxides 
to thromboxane A^ by the microsomal enzyme thromboxane synthetase and is 
formed in equimolar amounts (Diczfalusy e t  aly 1977). However malondialdehyde 
may also be formed non-enzymatically from prostaglandin endoperoxides.
Stuart e t  a l (1979) had previously shown that platelets obtained from 
pregnant diabetic women synthesized increased amounts of malondialdehyde 
and McGuire e t  a l (1978) had demonstrated increased malondialdehyde 
production in  v i t r o  by platelets from patients with diabetes mellitus.
In the present study a highly significant increase was observed in
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malondialdehyde formation in platelets from diabetic subjects compared 
to controls. This finding suggests that diabetic platelet may have 
enhanced activity of the thromboxane synthetase pathway when stimulated 
with arachidonic acid. Janka e t a t (1983) measured malondialdehyde 
formation in platelets stimulated by n-ethyl-maleimide (1 mM) from 
diabetics with and without clinical evidence of retinopathy. These 
authors found that platelets from retinopathy patients formed more 
malondialdehyde than platelets from patients without retinopathy but 
there was no difference between non-retinopathy patients and controls.
In the present study there were insufficient patients with retinopathy 
in whom malondialdehyde formation was measured to make a meaningful 
analysis. It is possible that the differing results between the study 
of Janka e t a t (1983) and the present study relate to the different 
techniques used.
There are several studies in the literature which have assessed 
thromboxane formation by the measurement of thromboxane by 
radioimmunoassay. Thromboxane A^ spontaneously rearranges to form 
thromboxane B^ which is stable and considerably less potent (Friedman 
e t d l (1979). Using this technique Butkus e t d l (1980) measured thromboxane 
B^ generation in platelets in response to exogenous arachidonic acid 
quantitated by electron-capture gas chromatography in a group of 180 
insulin-dependent diabetics. Although platelet thromboxane generation 
was elevated in diabetics without clinical evidence of vascular disease 
the difference did not reach statistical significance. However those 
diabetics with retinopathy, neuropathy, nephropathy, peripheral vascular 
disease or coronary vascular disease did show significantly enhanced 
platelet thromboxane generation compared to controls (Butkus e t  dly 1980). 
Ziboh e t d l (1979) also found that those diabetics with complications
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had higher platelet thromboxane generation than diabetics without 
complications. However in the study of Halushka e t  a i (1981) thromboxane 
generation appeared to be increased in diabetics without complications.
In addition evidence of increased thromboxane generation comes from 
studies using experimental animals. For instance the spontaneously 
diabetic BB-Wistar rat (Subbiah e t a i 1980 and the streptozotocin diabetic 
rat (Johnson e t a i 1980). In a recent study Butkus e t a i (1982) have 
assessed platelet thromboxane production in insulin-dependent diabetics 
with and without coronary artery disease. Platelets from diabetics 
with coronary artery disease had higher thromboxane production than those
r '
without coronary disease and diabetic platelets in general produced more 
thromboxane than non-diabetic platelets. It would appear therefore from 
this and the other studies cited that the weight of evidence supports the 
finding reported in this thesis of increased thromboxane production in 
the platelets of some diabetic subjects whether measured as malondialdehyde 
formation or thromboxane B2 levels. In addition those diabetics with 
vascular complications tend to show higher levels of thromboxane production 
than those diabetics free of complications.
Some support for the concept that increased thromboxane synthesis in 
platelets from diabetic subjects results from the altered metabolism of 
the diabetic state rather than being secondary to pre-existing vascular 
disease comes from studies which have correlated thromboxane production 
with diabetic control. Halushka e t aZ (1981) found a significant positive 
correlation between fasting plasma glucose concentrations and platelet 
thromboxane production stimulated by arachidonic acid in a group of 
15 diabetics. In addition platelet thromboxane synthesis was lower in 
a group of diabetics treated with constant subcutaneous insulin infusion 
for 6 months compared to a control group on conventional therapy (McDonald,
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e t  a l 1982). However when normal platelets were incubated with increasing 
glucose concentrations 'in v i t r o , thromboxane production was unaffected 
(Best e t  a t  1979) and the findings of Halushka e t  a t (1981) and McDonald 
e t  a t (1982) have not been supported by a recent study of platelet 
thromboxane generation before and after constant subcutaneous insulin 
infusion (Jackson e t  a t 1984). These authors measured platelet thromboxane 
generation in response to arachidonic acid and collagen in a group of 
11 diabetic patients with neuropathy. Prior to the start of therapy 
with constant subcutaneous infusion# thromboxane production was enhanced 
in the diabetics compared to controls and this enhanced production persisted 
after intensive therapy for 16 weeks. On the other hand collagen stimulated 
thromboxane production was similar in diabetics and controls prior to insulin 
infusion apart from at the lowest collagen concentration (0.5 yg/ml) when 
thromboxane production was in fact lower than that seen in control subjects. 
After insulin infusion this apparent subnormal thromboxane production 
returned to normal (Jackson e t  a t 1984). This finding may be due to a 
reduced level of arachidonic acid in platelet membrane phospholipids of 
diabetic subjects as described by Jones e t  a t (1983). This reduced level 
of arachidonic acid showed a negative correlation with glycosylated 
haemoglobin (Jones e t a t 1983). The finding therefore of an increase 
in collagen stimulated thromboxane production by insulin infusion could 
be explained by an increased availability of endogenous arachidonic acid 
from membrane phospholipids (Jackson e t  a t 1984).
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Platelet Sensitivity to Prostacyclin
An important and interesting finding to emerge from the studies 
undertaken for this thesis was that platelets from some diabetic patients 
appeared to have a marked reduction in sensitivity to the anti-aggregatory 
prostanoid, prostacyclin. This sensitivity was calculated as the amount 
of prostacyclin necessary to produce a 50% inhibition of ADP-induced- 
aggregation, the prostacyclin ID^^. Some 40% of the diabetics studied 
had prostacyclin levels greater than the highest value obtained in
control subjects. The control subjects used in this study were younger 
than the diabetic population and it is possible that the observed differences 
in sensitivity to prostacyclin between the two groups merely reflects age 
difference. However no correlation was found between the sensitivity 
of the platelets to prostacyclin with age in either diabetics or controls.
When the diabetic group was analysed according to the presence or 
absence of clinical evidence of large vessel disease, those diabetics 
with vascular disease had highly significantly decreased platelet sensitivity 
to prostacyclin. The sensitivity to prostacyclin of platelets from 
diabetics without clinical evidence of vascular disease compared to controls 
was diminished but this did not reach statistical significance. Therefore 
it is possible that the observed differences in prostacyclin sensitivity 
may reflect the presence of vascular disease in the diabetic group.
However the findings reported in this thesis from studies using the 
electronic platelet aggregometer where diabetic subjects were deliberately 
chosen because they were free of vascular disease support the finding of 
decreased sensitivity of diabetic platelets to prostacyclin. The 
findings of decreased sensitivity of diabetic platelets to prostacyclin 
in this thesis have been confirmed by a study from Japan (Onodera e t  a t  
1982).
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The reduced sensitivity of some diabetic platelets to prostacyclin 
remains to be explained. A possible explanation would be that the 
diabetic environment might affect the platelet receptors for prostacyclin. 
However prostacyclin receptors have been studied in diabetic platelets 
and no change in the number or affinity of membrane receptors was found 
(Dollery e t  a l 1983; Shepherd e t  a l 1983). In additioi\ prostcyclin- 
dependent activation of adenylate cyclase was similar in diabetics and 
controls (Dollery e t  a l 1983; Janka e t  a l 1983). However it has to be 
remembered that only 40% of diabetics showed reduced sensitivity to 
prostacyclin and in the above studies receptor binding and affinity and 
adenylate cyclase activity were not studied in platelets shown to have 
decreased prostacyclin senstivity.
Whole Blood Platelet Aggregation
Using the Chronolog Model 540 electronic aggregometer platelet 
responses to arachidonic acid, collagen and prostacyclin were studied in 
whole blood samples from diabetic subjects. Diabetic subjects showed 
enhanced platelet aggregation to both collagen (1 yg/ml) and arachidonic 
acid (1 mmol/1) and diminished sensitivity to prostacyclin.
This method of measuring platelet aggregation which was recently 
developed by Cardinal and Flower (1980) may have advantages over the 
turbidometric method of Born (1962). When two electrodes are suspended 
in stirred whole blood, a monolayer of platelets forms and the conductance 
between the electrodes is constant. When an aggregation agent is added, 
however, platelets aggregate to the monolayer and an accretion of platelets 
occurs between the two electrodes. This resulting increase in impedence 
between the electrodes can be observed on a pen recorder. The important 
difference between this technique and that of optical platelet aggregation 
is that platelet behaviour can be studied immediately after sampling because
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the centrifugation step (to produce PRP) is avoided.
In addition platelet responses are studied in the presence of formed 
blood elements and other potentially important but highly labile factors 
all of which may influence platelet behaviour. Before platelet 
aggregation can be studied using the optical method PRP 
has to be prepared. This may take 15-20 min and during this time labile 
modulators of platelet aggregation such as prostacyclin and thromboxane 
may have decayed to a great extent. In addition formed elements of 
blood may potentially affect platelet function by releasing platelet- 
active substances such as prostacyclin from leucocytes (Blackwell e t  a l  
1978) and ADP from red blood cells (Juhan e t d l 1982). The centrifugation 
step to prepare PRP may affect the population of the platelets 
studied as some platelets may be discarded with the red cells. For the 
above reasons the electronic whole blood aggregometer as described by 
Cardinal and Flower (1980) may be a more physiological approach to the 
study of platelet aggregation.
The results presented in this thesis using the new technique confirm 
previous studies of enhanced platelet aggregation in diabetic subjects 
using the optical aggregometer (discussed in thé'introduction). Care 
was taken in the choice of diabetic subjects for the study because as 
far as possible it was felt important to exclude diabetics with pre­
existing vascular disease as the point of the study was to determine 
whether platelet abnormalities were related to the metabolic abnormalities 
in diabetics rather than pre-existing vascular disease. Many of the 
early studies of platelet aggregation failed to make this distinction 
(see introduction). Although the presence of vascular disease cannot 
be completely excluded by thorough clinical assessment these results do 
suggest that thé platelet abnormalities in this diabetic group are due 
to the diabetic state. Further evidence to support this interpretation
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comes from the studies with prostacyclin. Platelet aggregation in 
whole blood from diabetic subjects showed reduced sensitivity to the 
anti-aggregatory effects of prostacyclin and a significant direct 
correlation was present between glycaemic control as assessed by levels 
of glycosylated haemoglobin and the prostacyclin ID^^. The reduced 
sensitivity of diabetic platelets to prostacyclin is in agreement with 
other results presented in this thesis using PRP in the optical aggregometer,
It is tempting to speculate that hyperglycaemia may directly affect 
platelet function by glycosylation of the platelet membrane but this
remains to be determined. Alternatively those diabetics with higher;
glycosylated haemoglobin levels may have other metabolic abnormalities 
such as hyperlipoproteinaemia as previously described in this thesis. 
Alternatively the altered platelet responsiveness in diabetes may be 
secondary to alterations to the vascular endothelium. Unfortunately 
it was not possible to make an indirect measurement of endothelial function 
in these patients by measurement of Factor VIII related antigen for instance.
The whole blood aggregometer has certain drawbacks compared to the 
optical aggregometer - it is certainly more difficult technically! In 
addition it is unable to record platelet shape change (Cardinal and Flower, 
1980). The failure to show differences between diabetics and control 
subjects with the higher dose of collagen (5 pg/ml) may also be related 
to the fact that the impedance aggregometer is more sensitive to smaller 
platelet aggregates than to the larger aggregates which would have been 
induced by the high dose collagen (Ingerman-Wojenski e t  dly 1982).
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Prostacyclin Production by Tissues from Pregnant Diabetic Rats
Discovery of the highly important cyclo-oxygenase product prostacyclin 
(Moncada e t  d l , 1976) which is the most potent endogenous anti-platelet 
aggregatory agent known has stimulated considerable interest in the 
possible effects of the diabetic state on its metabolism. Harrison e t a t
(1978) found decreased prostacyclin production in aortic rings taken from 
streptozotocin diabetic rats. This original observation has been confirmed 
and extended by other workers. Silberbauer e t d l (1980) induced a mild 
form of diabetes in Gottingen miniature pigs by repeated administration 
of streptozotocin. The amount of prostacyclin generated (assayed by 
inhibition of ADP-induced aggregation) by vascular tissue was significantly 
reduced in these mildly diabetic animals (Silberbauer e t  d l , 1980).
Recently Kern and Engerman (1984) have demonstrated a reduction in aortic 
6-oxo-prostaglandin production in diabetic dogs. The present study 
confirms these earlier findings in that prostacyclin production assayed 
by inhibition of ADP-induced aggregation was significantly reduced in aortic 
ring preparations. In addition it appears from the present study that 
the reduction of prostacyclin synthesis is related to the duration of the 
diabetic state. No significant difference was seen in prostacyclin 
production by tissues from control and acutely diabetic animals (diabetic 
for up to 15 days). On the other hand, a highly significant reduction 
in prostacyclin synthesis was observed in chronically diabetic rats 
(diabetic for up to 8 weeks). Similar findings have been reported by 
other workers. Rogers and Larkins (1981) studied the time course of 
diabetes on the production of 6-oxo-prostaglandin F^^ (the stable metabolite 
of prostacyclin) in aortic rings from streptozotocin diabetic rats. After 
two weeks of diabetes, 6-oxo-prostaglandin F^^ production did not differ 
between control and diabetic rats. However, 4 and 7 weeks
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after the induction of diabetes 6-oxo-prostaglandin production was 
significantly reduced even though the degree of hyperglycaemia and 
hypoinsulinaemia was the same as at 2 weeks.. The reduction in 6-oxo- 
prostaglandin Fj^ was not merely related to weight loss in the diabetic 
animals as in rats on a restricted dietary intake which led to weight 
loss, 6-oxo-prostaglandin Fj^ production remained unaffected.
In the present study an interesting finding in the pregnant diabetic 
rats was that even in chronically diabetic rats there was no reduction in 
prostacyclin production by myométrial tissue. It therefore appears that 
the effect of the diabetic state on prostacyclin production shows a degree 
of selectivity. However in other studies a reduced output of prostacyclin 
has been described in renal cortical tissue from chronically diabetic rats 
(Harrison e t  d l , 1978). This reduction may reflect decreased prostacyclin 
production by renal blood vessels as the renal cortex is a highly vascular 
tissue. In the myométrial tissue which showed no change in prostacyclin 
production secondary to the diabetic state the contribution of the blood 
vessels is minimal, the myométrial cells being the predominant source of 
prostacyclin (Williams e t d l , 1978).
The mechanism of the decreased prostacyclin production in vascular 
tissue from diabetic animals remains to be determined. It may be related 
to prostaglandin precursor availability. Mercurio e t  d l (1966) found 
depression of the microsomal desaturation of linoleic to gamma-linoleic 
acid in the alloxan diabetic rat and Jones e t  d l (1983) have found low 
phospholipid arachidonic acid levels in platelets from diabetics and an 
inverse correlation between the percentage of arachidonic acid and 
glycosylated haemoglobin concentrations. Other workers (Kalofoutis and 
Lekakis, 1981) found a higher percentage of arachidonic acid in diabetic 
platelets compared to controls. On the basis of altered substrate 
availability, however, it is difficult to envisage why the reduction in
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prostacyclin synthesis is selective for vascular tissue. Another 
alternative explanation for the selectivity of prostacyclin reduction 
by the diabetic state could relate to differences in phospholipase 
activities in the different tissues which could alter precursor 
availability and hence prostacyclin synthesis. Currently there is no 
information on this. A likely explanation for the reduced vascular 
prostacyclin production in diabetes may well be the increased level of 
lipid peroxides which are known to be present in diabetic animals 
(Higuchi, J982) and diabetic patients (Nishigaki e t d i , 1981) . These
peroxides are potent inhibitors of prostacyclin synthesis (Salmon e t  d l,
r
1978). This is supported by two recent studies which have examined the 
effect of the diabetic environment on prostacyclin production by cultured 
human endothelial cells (Paton e t a t , 1982; Patel and McEvoy, 1983).
When these cells were incubated with serum from diabetic patients 
prostacyclin production was inhibited. The nature of the inhibitory 
factor or factors in the diabetic serum is not understood but a likely 
contender would be lipid peroxides. This possibility is supported by 
the findings of Karpen e t a t (1982). These authors found that vitamin E 
treatment of diabetic rats reduced plasma lipid peroxide levels and along 
with this vascular prostacyclin production and thrombin-induced platelet 
thromboxane formation were restored to normal levels.
Some workers have been able to study the effect of diabetic treatment 
on prostacyclin production in experimental animals. Harrison e t  a l (1980) 
demonstrated that the reduced prostacyclin release (measured by bioassay) 
from aorta and renal cortex of streptozotocin-induced diabetic rats was 
restored to that seen in control non-diabetic rats by chronic (eight days) 
treatment with insulin. However no effects were seen on prostacyclin 
production immediately after the start of insulin treatment. It is likely 
that chronic insulin treatment is necessary to allow endothelial cell loss
133.
or damage to be repaired (Harrison e t d l , 1980). These findings have been 
extended in the streptozotocin diabetic rat by Rogers and Larkin (1981).
These authors measured the production of 6-oxo-prostaglandin by rat 
aorta. They demonstrated that the reduced production of 6-oxo-prostaglandin 
Fj^ seen in chronically diabetic rats (4-6 weeks) could be restored by a dose 
of insulin (8 units/kg/day) that only partially corrected plasma glucose 
levels and body weight.
It is obviously difficult to study arterial prostacyclin production 
in diabetic subjects. However in a small study of vascular tissue removed 
at operation prostacyclin generation was found to be reduced in tissue from 
diabetics (Johnson e t d l , 1979). Furthermore, Silberbauer e t  a l (1979) 
showed that vein biopsies obtained from insulin-dependent diabetics 
generated significantly less prostacyclin conçared to age- and sex-matched 
controls. On the other hand Davis e t a l (1981) found that venous 
prostacyclin production was lower in a small group of diabetics with nil 
or minimal retinopathy compared to diabetics with proliferative retinopathy. 
This finding albeit in very small numbers, would seem to suggest that 
reduced prostacyclin production may not have a role in the development of 
microvascular disease. However it is likely that this finding may indicate 
increased prostacyclin production in response to vascular injury (Dollery 
e t a l , 1983) .
Attempts have been made to measure plasma prostacyclin levels indirectly 
by measurement of 6-keto-prostaglandin Fj^ by radio immunoassay. Using 
this method conflicting findings have been reported in studies of diabetic 
subjects (Dollery e t d l , 1979; Davis e t  a l , 1979; Davis e t  a l , 1981) and 
it is now generally accepted that there may be considerable non-specific 
interference in assaying this metabolite in plasma which may explain the 
different findings (Dollery e t  a l , 1983; Greaves and Preston, 1982).
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Studies in Hyperlipldaemic Patients 
Platelet Specific Proteins
The major findings from the study of hyperlipidaemic subjects was that 
the platelet specific proteins, ^-thromboglobulin and platelet factor 4 
were highly significantly elevated in the subjects with primary hyperlipidaemia 
compared to age and sex-matched controls. Although, as with the studies 
in the diabetic subjects,there was much overlap between the control and 
patient groups 65% of the patients had levels of platelet specific 
proteins higher than the highest level seen in the control subjects. Again, 
as in the diabetic studies, there was a strong correlation between 
3“thromboglobulin levels and platelet factor 4 levels suggesting that both 
proteins were released from the same platelet pool and at the same rate.
Hyperlipidaemic subjects as discussed in the introduction to this 
thesis are at risk from premature vascular disease. It is likely therefore 
that the hyperlipidaemic subjects studied for this thesis as a group had 
more vascular disease (sub-clinical) than the age and sex-matched controls.
For this reason and the fact that 3-thromboglobulin is known to be elevated 
in a variety of vascular conditions (Ludlam e t  d l 1975;
Stewart e t a l 1983; Handin e t a l 1978; Celia e t  a l 1979) an extra control 
group of 57 patients with known peripheral vascular disease was included 
in this study. 3-Thromboglobulin levels in this group of vascular disease 
patients were elevated as expected when compared to the healthy control 
group. However in all types of hyperlipidaemic patients studied 
3-thromboglobulin levels were significantly higher than in the vascular 
disease patients. This important finding strongly suggests that the 
evidence of enhanced in  vivo release reaction as evidenced by the 
elevated 3~thromboglobulin levels is related in some way to the hyperlipidaemic 
state.
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The results reported here support previous studies of abnormal 
platelet function in hyperlipidaemic subjects (Colman, 1978; Shattil e t  
d l 1977; Carvalho e t  a l 1974; Joist e t  a l 1979; Tremoli e t  a l 1979; Nordoy 
and Rodset, 1971) which have measured in  v i t r o  platelet aggregation, 
platelet factor 4, plasma antiheparin activity and a bleeding time test. 
Carvalho e t  a l (1974) performed in  v i t r o  platelet aggregation studies on 
patients with familial type II hyperlipoproteinaemia (familial hyperchol- 
esterolaemia). Platelets from these subjects were found to be more 
sensitive to the aggregatory agonists adrenaline, collagen and ADP when 
compared to platelets from control subjects. In addition the platelet 
release reaction measured in  v i t r o  by the release of total nucleotides 
in response to the same three aggregating agents was increased. Eight 
of the patients studied had clinical evidence of atherosclerosis and the 
control subjects used were somewhat younger which may have to a certain 
extent influenced the results. However it does appear from the present 
study that these early in  v i t r o  findings of Carvalho e t a l (1974) are 
confirmed. On the other hand an interesting difference does emerge between 
the present study and that of Carvalho e t  a l with regard to subjects with 
type IV hyperlipoproteinaemia (elevated VLDL levels). Platelets from 
11 males with the type IV abnormality showed no evidence of increased 
sensitivity to aggregating agents in  v i t r o  in the early study. However 
in the present study reported in this thesis highly significant elevations 
of platelet specific proteins were seen in the patients with type IV 
hyperlipoproteinaemia. In this respect it is interesting that Joist e t a l  
(1979) who used the template bleeding time (as described by Mielke e t a l  
1969) as a measure of platelet function in  v ivo found shorter template 
bleeding times in 16 patients with type IV hyperlipoproteinaemia. In 
addition increased in  v it r o  aggregation has been described in a more 
recent study but only to adrenaline (Shastri e t  a l 1980). However Hassall
136.
e t a l 1983 who examined the relationship of in  v i t r o  aggregation to 
adrenaline, ADP, collagen and thrombin to prevailing lipid and lipoprotein 
concentrations in a normal male population found little relationship 
between VLDL and platelet sensitivity, except for a reduced adrenaline 
response in subjects in the lowest quintile for VLDL concentrations. In 
contrast total and LDL cholesterol concentrations did appear to influence 
platelet sensitivity to adrenaline and to a lesser extent ADP (Hassall e t  
a l , 1983). It would appear therefore that overall increased in  v it r o  
platelet aggregation appears to be more strongly related to LDL than 
VLDL. However Aviran and Brook (1983) have provided evidence for a 
direct effect on in  v i t r o  platelet function for both LDL and VLDL. These 
workers incubated the purified lipoproteins with gel-filtered platelets 
for 30 min at 37°C and demonstrated that VLDL and LDL increased thrombin- 
induced platelet aggregation and serotonin release induced by
adrenaline, ADP and thrombin. High VLDL levels leading to the laboratory 
classification of type IV hyperlipoproteinaemia may be caused by several 
pathological processes and VLDL composition as well as concentration may 
be affected. It is likely therefore that the variable results in the 
literature relating VLDL levels to platelet function may be related to 
these differences in VLDL.
Further evidence for the relationship of LDL to platelet function has 
come from a prospective study of a small group of patients with familial 
hypercholesterolaemia treated by plasmapheresis (Brook e t a l , 1983).
These authors demonstrated that following reduction of cholesterol levels 
after plasmapheresis there was a concurrent reduction in platelet aggregation 
and serotonin release.
The mechanism of cholesterol-induced effects on platelet function has 
received considerable attention. Shattil e t a l (1975) studied the effect 
of the plasma lipid environment of platelets on platelet sensitivity to
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aggregating agents in  v i t r o , Shattil e t a t (1975) incubated normal 
platelets with "cholesterol-rich" liposomes which led to a substantial 
increase in platelet cholesterol concentration (39.2% increase after 5 h).
The bulk of this increase in cholesterol (55%) was associated with tha 
membrane fraction. Along with these changes in cholesterol concentration 
the cholesterol-rich platelets showed enhanced sensitivity to adrenaline 
and ADP measured by aggregometry and f^^C] serotonin release. Conversely 
platelets incubated with "cholesterol-poor" liposomes showed a reduced 
cholesterol content (24% reduction) and a significantly reduced sensitivity 
to ADP. On the basis of these findings Shattil e t d l (1975) postulated 
that cholesterol enrichment of the platelet membrane might affect the membrane 
fluidity and consequently the sensitivity to aggregating agonists. In 
support of these findings the same workers (Shattil e t d l , 1977) found that 
platelets from patients with type II hyperlipoproteinaemia had a higher 
cholesterol/phospholipid ratio and other workers have found an elevated 
platelet-free cholesterol in patients with the same condition (Miettinen, 
1974). In addition Shattil and Cooper (1976) described increased platelet 
membrane microviscosity following incubation of platelets with "cholesterol- 
rich" liposomes and Sinha e t d l (1977) found an impaired response of the 
membrane associated enzyme adenylate cyclase to the stimulating effect of 
various agents including prostaglandin E^ as shown by a decrease in production 
of cyclic AMP. More recent studies have demonstrated that increases in 
the cholesterol/phospholipid ratio of platelets resulted in increased 
thrombin-induced aggregation and increased liberation of arachidonate 
XWorner and Patscheke, 1980). Jakubowski e t d l (1980) 
failed to show an increase in the cholesterol/phospholipid ratio in platelets 
obtained from 17 hypercholesterolaemic subjects compared to 17 age- and 
sex-matched controls. These hypercholesterolaemic subjects had lower
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plasma cholesterol levels than the subjects studied by Shattil e t d l
(1977). However Jakubowski e t  a l (1980) did show; that the platelets 
from the hypercholesterolaemic subjects had an impaired ability 
to accumulate cyclic AMP compared with controls when challenged with 
prostacyclin or prostaglandins and Ej. The failure of these authors 
to demonstrate quantitative changes in the cholesterol/phospholipid ratio 
of whole platelets does not rule out changes in membrane lipids as this 
may be masked if only the total platelet lipids are studied (Shattil e t  
a l , 1977). These findings of Jakubowski e t  a l (1980) of an impaired 
ability of whole platelets to accumulate cyclic AMP in response to 
prostacyclin do not appear to be explainable by changes in either affinity 
or number of prostacyclin receptors coupled to adenylate cyclase as Colli 
e t  a l (1983) could not demonstrate any differences between basal and 
prostacyclin stimulated adenylate cyclase activity in washed platelet 
membranes from subjects with hypercholesterolaemia compared to controls.
It is interesting therefore that the same authors showed decreased 
sensitivity of the hypercholesterolaemic platelets to the antiaggregatory 
effects of prostacyclin. The explanation for these findings remains to 
be clarified (Colli e t  a l , 1983).
From the findings reported in this thesis of evidence of enhanced 
in  vivo platelet release reaction in patients with hyperlipoproteinaemia 
together with the results of other studies outlined above it would appear 
that the lipid environment may have a direct effect on the metabolic 
responses of the platelet and these lipid/platelet interactions may well 
be of importance in the pathogenesis of atherosclerosis.
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Malondialdehyde Formation
Further evidence for the importance of lipid/platelet interactions 
comes from results presented in this thesis of increased malondialdehyde 
formation by washed platelets from hyperlipidaemic subjects, Malondialdehyde 
is a stable end-product of the prostaglandin pathway as discussed previously 
and was used as a convenient marker for the assessment of prostaglandin 
synthesis and particularly thromboxane synthesis. Increased malodialdehyde 
formation was found in both subjects with hypercholesterolaemia and 
hypertriglyceridaemia. These findings are in agreement with a small study 
reported by Tremoli e t a l (1979). These workers studied washed platelets 
from 4 patients with hypercholesterolaemia in response to stimulation with 
arachidonic acid (20 ymol/1) . Thromboxane the stable hydrolysis
product of thromboxane , measured by radioimmunoassay was significantly 
higher in hypercholesterolaemic platelets compared to controls and there 
was a highly significant positive correlation between platelet thromboxane 
B^ production and plasma cholesterol levels.
Support for these findings and evidence of a direct relationship 
between cholesterol and thromboxane synthesis has come from in  v itro  
studies. Beitz e t  a l (1983) have studied the effect of LDL isolated 
from healthy male volunteers on malondialdehyde formation as a marker of 
the activity of thromboxane synthetase by frozen human platelets. They 
found there was a dose-dependent stimulation of malondialdehyde formation 
from prostaglandin by LDL (0.5 - 2.0 mg LDL-cholesterol/ml) whereas 
no effect was seen with albumin or HDL (Beitz e t  a l , 1983). In addition 
Stuart e t a l (1980) altered platelet cholesterol content by incubation 
with 'bholestero1-rich" or 'fcholesterol-poor" liposomes and studied the 
influence of cholesterol content on platelet arachidonic acid metabolism. 
These workers demonstrated that thrombin when added to cholesterol-enriched 
platelets (pre-labelled with arachidonic acid) led to the release of
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significantly more arachidonic acid from pre-labelled platelet phospholipids 
compared to cholesterol-depleted platelets. Subsequent conversion of 
arachidonic acid to thromboxane B2 was also highly significantly enhanced 
in the cholesterol-rich platelets» Stuart e t  d l (1980) postulated that 
the increased thrombin-stimulated release of arachidonic acid from platelet 
phospholipids could be due to previously described effects of cholesterol on 
membrane fluidity (Shattil and Cooper, 1978) and that changes in membrane 
fluidity might affect the activity of the phospholipase enzyme which 
is principally responsible for the release of arachidonic acid. Further 
findings in this study may have a direct bearing on the findings of 
increased malondialdehyde formation in hypercholesterolaemic platelets 
reported in this thesis. Stuart e t  d l (1980) demonstrated both thromboxane 
B^ and the hydroxy fatty acid 12 L-hydroxy-5,8,10,heptadecatrienoic acid 
(HHT) production from arachidonic acid was increased in the "cholesterol- 
rich" platelets. It is important to bear in mind that malondialdehyde 
formation is not just a function of the activity of the enzyme thromboxane 
synthetase. Indeed a major alternative pathway for the metabolism of the 
cyclic endoperoxides is by further degradation to HHT and malondialdehyde 
(Moncada and Vane, 1978). Therefore the increase in HHT and thromboxane 
B^ formation suggests that enhanced conversion of arachidonic acid in 
"cholesterol-rich" platelets is probably due to enhanced activity of 
the cyclo-oxygenase enzyme since this enzyme rather than thromboxane 
synthetase which acts subsequently, is rate determining for the reaction 
(Stuart e t d l , 1980). In a recent study Tandon e t  d l (1983) have examined 
the effect of cholesterol loading of platelets, leading to changes in 
membrane microviscosity,on thrombin receptors. They showed that the 
number of thrombin receptors increased with increasing membrane viscosity 
while binding affinity decreased. Receptor number appeared to be the 
principal determinant of platelet responsiveness, however coupling between
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occupied receptor and bioresponse was unaffected by changes in membrane 
viscosity (Tandon e t  a t , 1983).
Evidence of increased platelet malondialdehyde formation in hyper­
cholesterolaemic individuals presented in this thesis gives support to an 
attractive hypothesis proposed by Fogelman e t  a t (1980) which may have 
important consequences for platelet/lipid interactions. As discussed 
in the introduction to this thesis platelet-derived growth factor released 
from the alpha-granules of platelets may have marked effects on lipoprotein 
cell interactions. In addition malondialdehyde may also be an important 
platelet product capable of such effects. The foam cells so characteristic 
of atheroma may have their origin in macrophage-monocytes which have 
receptors for chemically altered LDL. Unlike normal LDL receptors they 
are not down regulated by increasing cellular cholesterol concentration 
(Goldstein e t  a t , 1979). One type of chemically altered LDL taken up by 
macrophages resulting in massive cholesterol accumulation in these cells 
is malondialdehyde-modified LDL (Fogelman e t a t , 1980). The hypothesis 
would be that malondialdehyde, a stable end-product of the prostaglandin 
cascade released from platelets could lead to chemical modification of 
LDL rendering it recognisable by macrophage receptors leading to cholesterol 
accumulation in these cells.
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Summary
The results reported in this thesis suggest that in diabetic and 
hyperlipidaemic subjects, two groups at risk from premature vascular 
disease, platelet function as assessed by measurement of the platelet- 
specific proteins (markers of in  v ivo platelet release reaction) is 
enhanced. In addition the activity of the prostaglandin pathway in 
response to stimulation with arachidonic acid is increased as evidenced 
by increased malondialdehyde formation. In addition, in diabetic 
subjects whole blood platelet aggregation is enhanced; platelet 
prostacyclin sensitivity is reduced and in diabetic animals aortic 
prostacyclin production is reduced. Overall these findings appear to 
be related to the altered metabolic state found in diabetes and hyper­
lipidaemia rather than to pre-existing vascular disease. These 
alterations in platelet function may contribute to the increased vascular 
risk seen in these subjects. However more work is needed to pin-point 
the exact pathophysiology of platelet abnormalities in these conditions 
particularly whether they are secondary to endothelial cell malfunction.
In terms of therapeutic intervention the studies reported here argue for 
careful diabetic control not only in terms of glycaemic control but also 
for the achievement of normolipaemia. For the hyperlipidaemic subjects 
they provide a further justification for treatment of their high lipid 
levels. However it must be remembered that there are as yet no prospective 
epidemiological studies relating platelet function to the development of 
vascular disease as no satisfactory assessment of platelet function is 
available for such studies. In addition studies of a prospective nature 
which have intervened with platelet-active drugs throw no light on the 
'platelet hypothesis' as as yet there is no satisfactory drug available.
143
Until there are more satisfactory measures of overall platelet function 
and effective therapeutic interventions which can be put to the test in 
carefully controlled prospective studies then the conclusions of the work 
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